

May 2013

**CURRICULUM VITAE**

**NAME:** Candace Susanne Brown, MSN, PharmD

**BIRTH DATE:** January 26, 1949

**SOCIAL SECURITY NO:** 393-48-9350

**MARITAL STATUS:** Married

**OFFICE ADDRESS:** University of Tennessee Health Science Center  
Department of Clinical Pharmacy  
881 Madison Avenue, Room 458  
Memphis, TN 38163  
Phone: 901-412-4341  
Fax: 901-867-0749  
E-mail: csbrown@uthsc.edu

**CLINIC ADDRESS:** Women's Health Specialists  
7800 Wolf Trail Cove  
Germantown, TN 38138  
Phone: 901-682-9222  
Fax: 901-682-9505

**EDUCATION:**

**Undergraduate:**

Central Washington University  
Ellensburg, WA 09/68 - 06/71  
B.S. Psychology, 06/71

University of Washington  
Seattle, WA 09/74 - 06/77  
B.S. Pharmacy, 06/77

University of Alaska  
Anchorage, AK 09/78 - 03/82  
B.S. Nursing, 03/82 (*Cum Laude*)

**Graduate/Professional School:**

Central Washington University  
Ellensburg, WA 09/71 - 09/74  
M.S. Psychology, 09/74 (*High Distinction*)  
T. DeVietti, Ph.D., Preceptor

University of Washington  
Seattle, WA 06/83 - 06/85  
Doctor of Pharmacy, 06/85  
J. Koup, Pharm.D., Preceptor

University of Tennessee  
Memphis, TN 6/94 - 6/96  
M.S Nursing  
Sharon Scandrett, Ph.D., Preceptor

**Internship:**

Children's Orthopedic Hospital  
Pediatrics  
Seattle, WA 09/76 - 06/77  
R. Marshall, R.Ph., Preceptor

**Residency:**

General Adult (ASHP accredited)  
V.D.P. Burkhart, M.S., Preceptor  
Harborview Medical Center  
Seattle, WA 06/83 - 06/85

**Fellowship:**

Postdoctoral Fellowship in Psychopharmacotherapy  
R.M. Rose, M.D., S.G. Bryant, Pharm.D., Preceptors  
Department of Psychiatry  
University of Texas Medical Branch  
Galveston, TX 07/85 - 07/87

**Other Postgraduate Training:**

Postgraduate Psychotherapy Supervision  
Clinical Psychiatric Nurse Specialist Certification (R.N., C.S.)  
D. Allen, M.D., R. Farmer, M.D., S. Canfield, R.N.C.S.  
Department of Psychiatry  
University of Tennessee at Memphis 7/96 - 6/97

Postgraduate Sex Therapy Supervision  
 Sandra Leiblum, PhD  
 Department of Psychiatry  
 University Medical and Dental School of New Jersey (UMDNJ)  
 Piscataway, NJ 9/03 – 3/05

Postgraduate Sex Therapy Supervision  
 Ginger Manley, MSN, RN, CS  
 Franklin, TN 6/03 – 3/05

## **HONORS/AWARDS:**

### **Honorary Organizations:**

Phi Lambda Sigma National Pharmacy Leadership Society, Theta Chapter, 1987  
 Sigma Theta Tau International Honor Society of Nursing, Theta Omicron Chapter, 1987

### **National Awards:**

Outstanding Doctor of Pharmacy Student (Ciba Award), 1985  
 Mead Johnson CNS Research Award (ASHP), 1992  
 Upjohn CNS Research Award (ACCP), 1993  
 American College of Obstetricians & Gynecologists (ACOG), 3rd prize paper, 1994  
 American College of Obstetricians & Gynecologists (ACOG), Paper presentation, 2001  
 American College of Obstetricians & Gynecologists (ACOG)/Berlex, Inc., Research Award  
 in PMS/PMDD – Preceptor for Ob/Gyn Resident, 2006

## **MILITARY SERVICE:**

None

## **BOARD CERTIFICATION:**

American Nurses Credentialing Center, Family Nurse Practitioner (ARNP), Certification No:  
 0257439-22, 9/01/96 - 8/31/16.

American Nurses Credentialing Center, Clinical Specialist in Adult Psychiatric and Mental  
 Health Nursing (RN, CS), Certification No: 0284983-01, 9/01/97 - 8/31/12.

American Association of Sex Educators, Counselors and Therapists (AASECT)  
 Certification, Sex Therapist (4/05 – 12/31/12).

Board of Pharmaceutical Specialty, Psychiatric Pharmacy (BCPP), 4/1/97 - 12/31/11.

## **CERTIFICATION PROGRAMS:**

Immunization Program, American Pharmaceutical Association (APhA), September, 1998.  
 Good Clinical Practices (GCP), The Institute for Applied Pharmaceutical Sciences, May,  
 1999.

**LICENSURE:****Pharmacy:**

Tennessee, #C007154, 6/30/1988 - 6/30/14 Active.  
 California, #RPH 31821, 10/31/1978-10/31/13, Active.  
 Washington, #262-0301-10291, 1/26/78-1/26/03, Inactive.

**Nursing:**

Tennessee, #APN006384, 1/31/96-1/31/15, (Advanced Practice Nurse, APN),  
 (Nurse Practitioner with Certificate, #0991) Active  
 Tennessee, (Registered Nurse) #081938, 1/31/90-1/31/15 Active.  
 New Jersey, (RN, Advanced Practice Nurse) #26NJ00049000, 2004-2007, Inactive

**DEA License:** MB0501886, 6/02/05-07/31/14, Active.

**National Provider Identifier (NPI):** 1023012663

**SOCIETY MEMBERSHIPS:**

American Academy of Nurse Practitioners (AANP)  
 American Association of Colleges of Pharmacy (AACCP)  
 American Association of Sex Educators, Counselors and Therapists (AASECT)  
 American College of Clinical Pharmacology (ACCP), Fellow (FCP)  
 American College of Clinical Pharmacy (ACCP)  
 American College of Obstetricians and Gynecologists (ACOG), Educational Affiliate  
 American Society of Health-System Pharmacists (ASHP)  
 College of Psychiatric and Neurologic Pharmacists (CPNP), Founding Member  
 International Society for the Study of Women's Sexual Health (ISSWSH)  
 Sigma Theta Tau International Honor Society of Nursing, Theta Omicron Chapter  
 Society for the Scientific Study of Sexuality (SSSS)  
 Society for Sex Therapy and Research (SSTAR)

**UNIVERSITY AND COLLEGE APPOINTMENTS:**

Professor (Tenured), Department of Pharmacy, Primary Appointment, University of Tennessee, Memphis, TN, 1998-present

Professor, Department of Psychiatry, Secondary Appointment, University of Tennessee, Memphis, TN, 1999-present.

Professor, Department of Obstetrics and Gynecology, Secondary Appointment, University of Tennessee, Memphis, TN, 1999-present.

Associate Professor (Tenured), Department of Pharmacy, University of Tennessee, Memphis, TN, 1993-98.

Associate Professor, Department of Psychiatry, University of Tennessee, Memphis, TN, 1993-99.

Associate Professor, Department of Obstetrics and Gynecology, University of Tennessee, Memphis, TN, 1997-99.

Director, Mental Health Pharmacy Programs, Department of Clinical Pharmacy, University of Tennessee, Memphis, TN, 1992-93.

Assistant Professor, Department of Pharmacy, University of Tennessee, Memphis, TN, 1987-93.

Assistant Professor, Department of Psychiatry, University of Tennessee, Memphis, TN, 1990-93.

Assistant Professor, Department of Obstetrics and Gynecology, University of Tennessee, Memphis, TN, 1995-97.

Faculty, Center for Pediatric Pharmacokinetics and Therapeutics, University of Tennessee, Memphis, TN, 1989-93.

Instructor, College of Pharmacy, University of Texas, Austin, TX, 1985-87.

Instructor, School of Nursing, University of Alaska, Anchorage, AK, 1983-85.

#### **HOSPITAL/CLINICAL APPOINTMENTS:**

Women's Health Specialists, 7800 Wolf Trail Cove, Germantown, TN 38138, 2005-2012.

Southeast Urology Network, 995 S. Yates, Suite 1, Memphis, TN 38119, 2005-2007.

UT Medical Group, Inc., Obstetrics and Gynecology, 7945 Wolf River Blvd, Germantown, TN, 2001-2005.

UT Medical Group, Inc., Obstetrics and Gynecology, 909 Ridgeway Loop, Memphis, TN, 1992-2001.

#### **PRACTICE/PROFESSIONAL EXPERIENCE:**

Certified Sex Therapist, Women's Health Specialists. Memphis, TN, 2005-2012.

Psychiatric Family Nurse Practitioner (PFNP), Women's Health Specialists, Memphis, TN, 2005-2012.

Certified Sex Therapist, Southeast Urology Network, Memphis, TN, 2005-2007.

Psychiatric Family Nurse Practitioner (PFNP), Southeast Urology Network, Memphis, TN, 2005-2007.

Psychiatric Family Nurse Practitioner (PFNP), Department of Obstetrics & Gynecology, UT Medical Group, Memphis, TN, 1996-2005.

Pharm.D. Practitioner, UT Medical Group, Memphis, TN, 1992-1996.

Psychopharmacy Clinician, Midtown Mental Health Center, Memphis, TN, 1987-89.

Continuing Education Coordinator, Department of Continuing Education, Providence Hospital, Anchorage, AK, 1982-83.

Community Pharmacist, Pan-N-Save Corporation, Anchorage, AK, 1978-82.

Inpatient Hospital Pharmacist, Children's Orthopedic Hospital, Seattle, WA, 1977-78.

### **OTHER ACADEMIC APPOINTMENTS**

Clinical Professor, Department of Obstetrics, Gynecology, and Reproductive Sciences, Robert Wood Johnson Medical School, University of Medicine & Dentistry of New Jersey (UMDNJ), Piscataway, NJ, 2003-present.

Adjunct Assistant Professor, Department of Psychology, University of Memphis, Memphis, TN, 1989-93.

### **PRIVATE SECTOR APPOINTMENTS:**

Director, Center for Sexual Health and Wellness, Women's Health Specialists, 7800 Wolf Trail Cove, Germantown, TN 38138, 2005-2012.

### **TEACHING EXPERIENCE:**

#### **College of Pharmacy:**

Clinical Rotation Preceptor, Women's Health Research, 11 student mo. 2011-Present  
 Lecturer, Pharmacotherapy Grand Rounds, 4 contact hours, Lincoln Memorial University (LMU) School of Osteopathy, Harrogate, TN, 2009  
 Lecturer, Nonprescription Drugs, Menstrual Disorders, 1 contact hour, 2003-Present  
 Lecturer, Therapeutics III, Sexual Disorders, 1 contact hour, 2008-present  
 Course Director, Therapeutics V, 4 credit hours, 2002-2003  
 Course Director, Women's Health Selective, 3 contact hours, 2001-2010  
 Lecturer, Patient Assessment, 16 contact hours, 1998-2000.  
 Clinical Rotation Preceptor, Women's Health, 11 student months, 1996-2011.  
 Course Director, Patient Assessment, 2 credit hours, 1987-89, 1996-98.  
 Lecturer, Psychopharmacy Selective, 1 contact hour, 1995-96.  
 Lecturer, Therapeutics III, Reproductive System, 1 contact hour, 1995-96.  
 Lecturer, Therapeutics IV, Dermatology, 1 contact hour, 1995-96.  
 Lecturer, Therapeutics IV, DSM-IV Classifications, 1 contact hour, 1994-98.  
 Lecturer, Therapeutics IV, Major Depression, 1 contact hour, 1994-99.

Lecturer, Therapeutics IV, Bipolar Disorder, 1 contact hour, 1994-1999.  
 Lecturer, Therapeutics IV, Mental Status Exam, 1 contact hour, 1993-95.  
 Lecturer, Clinical Pharmacokinetics, 1 contact hour, 1990-92.  
 Course Director, Psychotherapeutics, 2 credit hours, 1989-93.  
 Lecturer, Therapeutics III, PMS/Dysmenorrhea, 1 contact hour, 1989-95.  
 Clinical Rotation Preceptor, Mental Health, 6 student months, 1987-96.  
 Lecturer, Experimental Design/Data Interpretation, 1 contact hour, 1987-93.  
 Lecturer, Drug Information/Literature Evaluation, 1 contact hour, 1987-95.

### **College of Nursing:**

Consultant, National Institute of Health (K 23). Patient Oriented Research Award, "Predictors of Sexual Function and Quality of Life Following Vulvar Excision. Principal Investigator: WM Likes, 2006-2009.

Lecturer, Nurse Practitioner Graduate Students, Premenstrual Syndrome, 1 contact hour, 1996-99.

Doctoral (DNS) Committee Wendy Likes, "Validation of the Female Sexual Function Inventory in Women with Gynecologic Cancer," University of Tennessee, Memphis, Tennessee, 2004-2005.

### **College of Medicine:**

Lecturer, Psychiatry Residents, Psychobiology Seminar, 2 contact hours, 1987-91.

Lecturer, Psychiatry Residents, Psychopharmacology Seminar, 2 contact hours, 1992-5.

Lecturer, Psychology Interns, Basic Pharmacology Seminar, 2 contact hour, 1990-94.

Preceptor, Cynthia Goldsmith-Fletcher, MD. Resident in Obstetrics/Gynecology, Sponsor, Research Project, "Predictors of Treatment Response in a Self-Report Survey of Vulvodynia Patients," University of Tennessee, Memphis, Tennessee, 2002-2003.

Preceptor, Tamra Fortenberry, MD. Resident in Obstetrics/Gynecology, Sponsor, Research Project, "A Comparison of Type and Severity of Premenstrual Symptoms occurring in African American and Caucasian Women with Premenstrual Dysphoric Disorder," University of Tennessee, Memphis, Tennessee, 2006-2007.

Lecturer, Obstetrics and Gynecology Residents, Sexual Medicine, 2 contact hours, 2008-2009.

### **VISITING PROFESSORSHIPS:**

Visiting Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, Women's Health Institute Robert Wood Johnson University Hospital, University of Medicine & Dentistry of New Jersey (UMDNJ), New Brunswick, NJ 9/03 – 3/14.

Visiting Professor, Department of Psychiatry, University Behavioral Health Care, University of Medicine & Dentistry of New Jersey (UMDNJ), Piscataway, NJ, 9/03 – 3/04.

## **INVITED LECTURES:**

### **National:**

National Institute of Health, National Institute of Child Health and Human Development (NICHD), "Development of Research Diagnostic Criteria in Vulvodynia", Vulvodynia: A Chronic Pain Condition Workshop, Bethesda, MD, May 2013.

National Institute of Health (NIH), National Institute of Child Health and Human Development (NICHD), Vulvodynia: A Chronic Pain Condition: Setting a Research Agenda, Potomac, MD, July 2011.

National Vulvodynia Association (NVA). "An open label trial of milnacipran in the treatment of women with provoked vestibulodynia," Vulvodynia: A Decade of Research Progress and Future Direction Needs, Chicago, IL, October 2010.

National Institute of Health (NIH), Office of Research on Women's Health (ORWH), "Vulvodynia: A State-of-the-Art Consensus and Definitions, Diagnosis and Management," Vulvodynia Awareness Campaign Conference, National Press Club, Washington, DC., October 2007.

Educare, "Sexuality after Breast Cancer," Advanced Breast Health Navigator Training, Myrtle Beach, SC, November 2006.

The Journal of Sexual Medicine Breakfast Debate. International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting. "A Women's Sexual Satisfaction from Intercourse is Not Related to Her Partner's Premature Ejaculation." Las Vegas, Nevada November 2005.

Moderator, Paper Session #5, "Validation of Female Sexual Dysfunction Questionnaires and Inventories," International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting, Atlanta, GA, October 2004.

National Association of Nurse Practitioners in Women's Health (NPWH) 7<sup>th</sup> Annual Conference, Women's Health Care in the New Millennium, "Female Sexual Arousal Disorder: Understanding Libido," Chicago, IL, October 2004.

Excel Continuing Education, Continued Medical Education, "Psychosocial Issues associated with Female Sexual Dysfunction," Charlotte, NC, July 2004.

Excel Continuing Education, Continued Medical Education, "Psychosocial Issues associated with Female Sexual Dysfunction," Atlanta, GA, June 2004.

Boston Psychopharmacology Institute, "Sexual Dysfunction," Boston, MA, June 2004.



Department of Psychiatry, University Behavioral Health Sciences, Robert Wood Johnson Medical School, University Medical and Dental School of New Jersey (UMDNJ), "2004 Human Sexuality Program: Changing the Paradigm," Group Leader, January 2004.

Department of Psychiatry, University Behavioral Health Sciences, Robert Wood Johnson Medical School, University Medical and Dental School of New Jersey (UMDNJ), 2004 Human Sexuality Program: Changing the Paradigm: "Sex and the Sacred," Co-facilitator with Sarah Karl, PhD, January, 2004

American Society of Health-System Pharmacists (ASHP), Clinical Midyear Meeting, "Pearls in Women's Health", Atlanta, GA, December 2002.

American College of Clinical Pharmacy (ACCP) Annual Meeting, "Issues in Women's Health Pharmacotherapy: Androgens in Women," Albuquerque, NW, October 2002.

College of Psychiatric and Neurologic Clinical Pharmacists (CPNP), 5<sup>th</sup> Annual Meeting, "The Treatment of Female Sexual Function as a Quality of Life Enhancer," Seattle, WA, April 2002.

Zynx Health Inc., "Evidence-Based Approach to the Management of PMS and PMDD." Chicago, IL, March 2002.

Berlex Laboratories, Inc., 2002 Female Health Care Visiting Faculty Program, "From Menarche through Menopause," Las Vegas, NV, March 2002.

National Community Pharmacists Association (NCPA), 103<sup>rd</sup> Annual Convention, Contraceptive Methods and Counseling Strategies for Improving Compliance, "Use and Misuse of Oral Contraceptives," Philadelphia, PA, October 2001.

National Community Pharmacists Association (NCPA), 103<sup>rd</sup> Annual Convention, Contraceptive Methods and Counseling Strategies for Improving Compliance, "New Developments in Contraception," Philadelphia, PA, October 2001.

National Association of Nurse Practitioners in Women's Health (NPWH) Conference, Beyond Contraception: Enhancing the Quality of Life, "Effect of a New Monophasic Oral Contraceptive on Premenstrual Symptoms PMS/PMDD," Orlando, FL, October 2001.

American College of Clinical Pharmacy (ACCP), Annual Meeting, "Pharmacotherapy Innovations: Uncommon Treatments for Common Diseases: Sexual Dysfunction (Male and Female)," Moderator, Tampa, FL, October 2001.

American College of Clinical Pharmacy (ACCP), 2001 Updates in Therapeutics: The Pharmacotherapy, Nutrition Support, Oncology, and Psychiatry Pharmacy Preparatory Courses, "Major Depressive Disorder," Salt Lake City, UT, April 2001.

American College of Clinical Pharmacy (ACCP), 2001 Updates in Therapeutics: The Pharmacotherapy, Nutrition Support, Oncology, and Psychiatry Pharmacy Preparatory Courses, "Bipolar Disorder," Salt Lake City, UT, April 2001.

American Pharmaceutical Association (APhA), 148<sup>th</sup> Annual Meeting & Exposition, "Therapeutic Update: PMS & Premenstrual Dysphoric Disorder," San Francisco, CA, March 2001.

American College of Clinical Pharmacy (ACCP), 2000 Updates in Therapeutics: The Pharmacotherapy, Nutrition Support, Oncology, and Psychiatry Pharmacy Preparatory Courses, "Major Depressive Disorder," St. Louis, MO, June 2000.

American College of Clinical Pharmacy (ACCP), 2000 Updates in Therapeutics: The Pharmacotherapy, Nutrition Support, Oncology, and Psychiatry Pharmacy Preparatory Courses, "Bipolar Disorder," St. Louis, MO, June 2000.

College of Psychiatric and Neurologic Pharmacists (CPNP), 3<sup>rd</sup> Annual Meeting, "Treatment of Chronic Pelvic Pain," Washington, DC May 2000.

American Pharmaceutical Association (APhA), 147<sup>th</sup> Annual Meeting & Exposition, "Beyond Depression: New and Emerging Uses for SSRIs," Washington, DC, March 2000.

American College of Clinical Pharmacy (ACCP), Annual Meeting, "Efficacy and Potential Toxicity of St. John's Wort," Kansas City, MO, October 1999.

Pro/Health, Professional Healthcare Communications Consensus and Planning Meeting on "Evidence-Based Guidelines for PMS," McLean, VA, June 1999.

American Society of Health-System Pharmacists (ASHP), Clinical Midyear Meeting, "Managing Depression in Pregnant and Breast-feeding Women," Las Vegas, Nevada, December 1998.

The American Journal of Managed Care. Roundtable Discussion on Migraine Management, San Diego, CA, October 1998.

American College of Clinical Pharmacy (ACCP), Women's Health PRN Section, "Psychotropic Induced Sexual Dysfunction," Nashville, TN, August 1996.

The Philadelphia College of Pharmacy and Science Consensus Roundtable Meeting, "Advances in Hormone Replacement Therapy," Atlanta, GA, May 1996.

American College of Clinical Pharmacy, (ACCP) Annual Meeting, "Postpartum Depression," Washington, D.C., August 1995.

American Society of Hospital Pharmacists (ASHP), Clinical Midyear Meeting, "PTSD: Current Issues and Treatment Strategies," Miami, Florida, December 1994.

American College of Clinical Pharmacology 22nd Annual Meeting, "Women and Cardiovascular Disease," Boston, MA, November 1993.

American Society of Parenteral and Enteral Nutrition (A.S.P.E.N.), 16th Clinical Congress Workshop, "Amino Acids as Neurotransmitters: Modulators of PMS," Orlando, FL, January 1992.

American Association of Clinical Pharmacy (AACCP) 11th Annual Meeting, "Concentration-Response Relationship of Imipramine in the Treatment of Attention-Deficit Hyperactivity Disorder," San Francisco, CA, August 1990.

Bristol Myers Annual Speakers' Bureau Symposium, "Efficacy of Buspirone in PMS with Biological Correlates," Scottsdale, AZ, March 1990.

American Society of Hospital Pharmacists (ASHP) Clinical Midyear Meeting, "Applications of Biological Markers to Psychiatric Research," Psychopharmacy SIG Section, Atlanta, GA, December 1989.

National Institute of Health Program (NIH) Project Site Visit, "Markers of Depression in Epilepsy," Memphis, TN, April 1989.

American Association of Colleges of Pharmacy (AACCP) Annual Meeting, "Concentration-Response Relationship of Nadolol in the Treatment of Antipsychotic-induced Akathisia," Chicago, IL, July 1988.

### **Regional:**

Osteopathic Students, Lincoln Memorial University (LMU) Pharmacotherapy Grand Rounds, "Drugs in Lactation: Case Presentation", St. Mary's Hospital, Knoxville, TN, July 2009.

Osteopathic Students, Lincoln Memorial University (LMU) Pharmacotherapy Grand Rounds, "Gynecologic Disorders: Case Presentation", St Mary's Hospital, Knoxville, TN, TN, July 2009.

Osteopathic Students, Lincoln Memorial University (LMU) Pharmacotherapy Grand Rounds, "Contraception: Case Presentation", Nashville, TN, July 2009.

Osteopathic Students, Lincoln Memorial University (LMU) Pharmacotherapy Grand Rounds, "Pregnancy: Case Presentation", Nashville, TN, July 2009.

Department of Obstetrics and Gynecology and Reproductive Sciences Grand Rounds, Robert Wood Johnson Medical School, University Medical and Dental School (UMDNJ), "Treatment of Vestibulodynia with Botulinum Toxin Type A," New Brunswick, NJ, September, 2006.

American College of Obstetricians and Gynecologists (ACOG), 12<sup>th</sup> Annual Clinical Meeting, "The Hypoandrogenic Woman," Sunriver, Oregon, April 2005.

American College of Obstetricians and Gynecologists (ACOG), 12<sup>th</sup> Annual Clinical Meeting, "Testosterone and Beyond: New Therapies for Female Sexual Dysfunction," Sunriver, Oregon, April 2005.

Female Health Care CME Dinner Meeting, Noncontraceptive Benefits of Oral Contraceptives – The Basis for Individual Choice," Chattanooga, TN, April 2004.

Women's Health Connection, Robert Wood Johnson Medical School, University Medical and Dental School (UMDNJ), "Effects of Menstrual Cycle on Medical Conditions," Piscataway, NJ, February 2004.

Women's Health Connection, Robert Wood Johnson Medical School, University Medical and Dental School (UMDNJ), "Effects of Menstrual Cycle on Medical Conditions," New Brunswick, NJ, January 2004.

Department of Obstetrics and Gynecology, Jersey Shore Medical Center, "Effects of the Menstrual Cycle on Medical Conditions," Jersey Shore, NJ, November, 2003.

Department of Psychiatry, University Behavioral Health Sciences, Robert Wood Johnson Medical School, University Medical and Dental School of New Jersey (UMDNJ), "Vaginismus," November, 2003.

Department of Psychiatry, University Behavioral Health Sciences, Robert Wood Johnson Medical School, University Medical and Dental School of New Jersey (UMDNJ), "Androgen Deficiency Syndrome and its Treatment," September, 2003.

University of Michigan College of Pharmacy's Tom D. Rowe 50<sup>th</sup> Annual Pharmacy Lectures Program, Drugs for Better Living: Quality of Life Enhancers, "New Guidelines for Treating PMS," Ann Arbor, MI, October 2001.

Chandler Medical Center, University of Kentucky, Lexington, Midwestern Neuro-Psychiatric Pharmacy Conference, "Management of Mood Disorders in Women: Pregnancy, Postpartum and Menopause," Lexington, KY, September 1999.

Forest Laboratories and Parke-Davis Speakers Bureau for Psychiatry, "Improving the Management of Depression with Selective Serotonergic Reuptake Inhibitors (SSRI)," Elam Mental Health Facility, Nashville, TN, September 1998.

Tennessee Society of Hospital Pharmacists (TSHP), 28th Annual Meeting, "Hormonal-Related Disorders and Mental Health," April 1998.

College of Pharmacy Depression Certificate Program, University of Tennessee, Memphis, "Postpartum Depression," Nashville, TN, October 1997.

College of Pharmacy Depression Certificate Program, "Bipolar Illness," Nashville, TN, October 1997.

College of Pharmacy 1997 Basic Pharmacology and Therapeutics, "Recent Developments in the Treatment of Bipolar Illness," Nashville, TN, October 1997.

College of Pharmacy Depression Certificate Program, University of Tennessee, Memphis, "Postpartum Depression," Knoxville, TN, October 1997.

College of Pharmacy Depression Certificate Program, "Bipolar Illness," Knoxville, TN, October 1997.

College of Pharmacy 1997 Basic Pharmacology and Therapeutics, "Recent Developments in the Treatment of Bipolar Illness," Knoxville, TN, October 1997.

South Carolina Society of Hospital Pharmacists' Meeting on Contemporary Issues in Women Health, "Premenstrual Syndrome," Charleston, SC, September 1997.

Michigan State Consortium of Pharmacists, "Signs and Symptoms of PMS," Toledo, OH, June 1996.

College of Nursing, "The Pharmacologic and Psychosocial Management of Premenstrual Syndrome," University of Utah, Salt Lake City, UT, April 1996.

Department of Psychiatry Research Group, "TRH-induced Prolactin Response in Late Luteal Phase Dysphoric Disorder," Vanderbilt University, Nashville, TN, October 1992.

Annual Pharmacy Lectures Program, "Pharmacologic Treatments in PMS," in Psychopharmacy: Advances in Drug Therapy Symposium, University of Michigan, Ann Arbor, MI, October 1991.

Northwest Tennessee Academy of Medicine, "Psychopharmacology of Anxiety," Dyersburg, TN, April 1991.

Jackson Hospital Physician Noon Conference, "Drug Therapy in PMS," Jackson, MS, October 1990.

Idaho State Pharmacy Association, "An Update on the Treatment of Depression," Sun Valley, ID, September 1990.

North Mississippi Medical Society Meeting, "An Update on the Treatment of Premenstrual Syndrome," Clarksdale, MS, April 1990.

Psychiatry Staff at San Antonio State Hospital, "Biological Markers in Psychiatry," San Antonio, TX, November 1989.

Kathryn Weil Center for Women's Life, "Understanding PMS," Lafayette, ID, May 1989.

Pharmacists' First Continuing Education Program, "Differential Diagnosis of Anxiety," Paris, TN, May 1988.

Department of Pharmacy Practice, "Clinical Guidelines in the Treatment of Aggression," University of New Mexico, Albuquerque, NM, January 1987.

**Local:**

University of Tennessee Family Medicine/Psychiatry CME Conference, "Understanding Female Sexuality," The Mind, Body & Soul, Memphis, TN Apr 2013.

University of Tennessee Health Sciences Center, Bioinformatics Seminar, "Challenges in Conducting a Multicenter Clinical Trial," Memphis, TN, Nov 2012.

University of Tennessee Health Science Center, Grant Rounds, Department of Psychiatry, "Vulvodynia", Memphis, TN, June 2012.

University of Tennessee Health Science Center, Monthly Research Presentation, Department of Obstetrics and Gynecology, "Vulvodynia," Memphis, TN, April 2012

Baptist Memorial Hospital Physicians Ob/Gyn Clinical Case Conference, "Diagnosis and Treatment of Vulvodynia", Memphis, TN, July 2011.

BioSante Pharmaceuticals, "Hot Flash Havoc", Memphis, TN, March 2011.

West Clinic Cancer Center, "Sexuality and Cancer in Women," Memphis, TN, April, 2010.

Baptist Centers for Cancer Care, Baptist East Hospital, "Sexuality and Cancer in Women," Germantown, TN, March, 2010.

"Body of Women – Everything you Wanted to Know". Midtown Small Business Owners, Memphis, TN January 2009.

American Cancer Society, "Regaining a Sex Life after Prostate Cancer: Beliefs, Truth, and Reality," Baptist Memorial Hospital for Women, Memphis, TN, March 2009.

"Efficacy of Single and Combined Therapy in Women with Provoked Vestibulodynia," Grand Rounds, Department of Clinical Pharmacy, Memphis, TN, November 2008.

Experiential Healing Center, "Healthy Female Sexuality," Memphis, TN, November 2008.

West Clinic Cancer Center, "Sexuality and Cancer in Women," Memphis, TN, October 2008.

University of Tennessee Health Sciences Center, Ob/Gyn Residents, "Conducting a Sexual Interview", Memphis, TN, September 2008.

American Cancer Society, "Regaining a Sex Life after Prostate Cancer: Beliefs, Truth, and Reality," Baptist Memorial Hospital for Women, Memphis, TN, May 2006.

American Cancer Society, "Regaining a Sex Life after Prostate Cancer: Beliefs, Truth, and Reality," Baptist Memorial Hospital for Women, Memphis, TN, December 2006.

UT Medical Group, Germantown OB/Gyn Noon Conference, "Herbal Products in the Treatment of Menopausal Symptoms," Germantown, TN, March 2003.

UT Medical Group, Germantown Ob/Gyn Noon Conference, "Treatment of Female Sexual Dysfunction," Germantown, TN, August 2002.

UT Department of Obstetrics and Gynecology, Annual Ob/Gyn Residency Program, "Treatment of Premenstrual Disorders," Cordova, TN, July 2002.

Department of Preventive Medicine Research Conference, "Treatment of Female Sexual Dysfunction," University of Tennessee, Memphis, TN, May 2002.

UT Medical Group, "Female Sexual Disorder," Web Chat, Channel 3, Memphis, TN, February 2002.

UT Medical Group, "Premenstrual Syndrome," Web Chat, Channel 3, Memphis, TN, December 2001.

UT Medical Group, "Premenstrual Syndrome," Germantown, TN, September 2001.

UT Medical Group, "Female Sexual Disorders," Germantown, TN, September 2001.

University of Tennessee Health Sciences Center, Office of Continuing Medical Education: Hot Topics in Women's Health Symposium: "Premenstrual Syndrome," Memphis, TN, November 2000.

First Annual Women's Health Week, "Healthy PMS Strategies," Memphis, TN, March 2000.

Germantown Health Fair, "Premenstrual Syndrome," Germantown, TN, February 2000.

U.S. Federal Deposit Insurance Corporation (FDIC), Lunch-n-Learn, "Holiday Depression," Memphis, TN, November 1999.

St. Ann Catholic Church Women's Health Issue Fair, "PMS or Menopause," Bartlett, TN, October 1999.

U.S. Federal Deposit Insurance Corporation (FDIC), Health Fair, "Women's Health," Memphis, TN, September 1999.

Greenwood CME Women's Health Fair, "Menopause-The Truth," Millington, TN, August 1999.

Enterprise Bank, WREG TV and UT Medical Group, "Today's Healthy Woman," Enterprise Bank, Memphis, TN, July 1999.

College of Nursing, University of Tennessee, Memphis, "Pharmacological Management of Sexual Dysfunction-Male and Female," Memphis, TN, March 1999.

Southern Women's Show, "The Truth About PMS," Memphis, TN, May 1998.

FedEx Women's Forum, "PMS," Adam's Mark Hotel, Memphis, TN, April 1998.

UTMG's Women's Health Forum, "Headaches, Hormones & PMS: Is There a Link?" Community Foundation of Greater Memphis, Memphis, TN, and Hope Presbyterian Church, Memphis, TN, March 1998.

College of Pharmacy Depression Certificate Program, University of Tennessee, Memphis, "Postpartum Depression," Memphis, TN, November 1997.

College of Pharmacy Depression Certificate Program, "Bipolar Illness," Memphis, TN, November 1997.

College of Pharmacy 1997 Basic Pharmacology and Therapeutics, "Recent Developments in the Treatment of Bipolar Illness," Memphis, TN, November 1997.

Tap Pharmaceutical's Contemporary Issues in Gynecology: Update for the 90's. "An Overview of the Management of PMS," Memphis, TN, August 1997.

Employee Wellness Program at First Tennessee Bank Employees, "Effect of PMS on Career and Family," Memphis, TN, July 1997.

Southern Women's Show, "Premenstrual Syndrome," Memphis, TN, April 1997.

Methodist - Germantown Monthly OB/GYN Evening Conference, "Current Management of PMS," Germantown, TN, March 1997.

Department of OB/GYN Grand Rounds, "Pharmacologic Management of PMS," University of Tennessee, Memphis, TN, August 1996.

Employee Wellness Program at First Tennessee Bank Employees, "Effect of PMS on Career and Family," Memphis, TN, August 1996.

Women Health Obstetrical and Neonatal Nurses, (AWHON), "An Overview of Treatment for PMS," Memphis, TN, April 1996.

Southern Women's Show, "Premenstrual Syndrome," Memphis, TN, April 1996.

College of Pharmacy, "Developing Basic Skills and Knowledge Base to Provide Pharmaceutical Care in a Rapidly Changing Health Care Arena: A Program for VA Staff Pharmacists," University of TN, Memphis, TN, January and February 1996.

Mid-South Family Nurse Practitioners (FNP), "Assessment of Premenstrual Syndrome," Memphis, TN, January 1996.

Veteran's Administration Medical Center Women's Clinic, "Assessment and Evaluation of PMS," Memphis, TN, January 1996.

Department of OB/GYN, Maternal Fetal Research Division of Research Nurses, "Evaluation and Treatment of Premenstrual Syndrome," University of Tennessee, Memphis, TN, November 1995.

Department of Psychiatry Grand Rounds, "Treatment of Postpartum Depression," University of Tennessee, Memphis, TN, September 1995.

Department of OB/GYN Grand Rounds, "Management of Postpartum Depression," University of Tennessee, Memphis, TN, July 1995.

Southern Women's Show, "Premenstrual Syndrome," Memphis, TN, March 1995.

University of Tennessee's Prevention Center Scientific Meeting, "Treatment of PMS with Leuprolide," University of Tennessee, Memphis, TN, June 1994.



Department of Psychiatry Grand Rounds, "Efficacy of Depot Leuprolide in PMS," University of Tennessee, Memphis, TN, October 1993.

Research Seminar in Clinical Pharmacy, "Efficacy of Depot Leuprolide in Suppressing Behavioral and Physical Symptoms of Premenstrual Syndrome," University of Tennessee, Memphis, TN, September 1993.

Department of Psychology, "The Psychologist's Role in Management of PMS," Memphis State University, Memphis, TN, April 1993.

National Electrolysis Education Seminar, "Dermatological Effects of Medications," Shelby State Community College, Memphis, TN, March 1993.

Department of Psychiatry Grand Rounds, "Differential Diagnosis of PMS from Other Underlying Psychiatric Disorders," University of Tennessee, Memphis, TN, November 1992.

HealthPlex Family Medicine Noon Conference, "Clinical Management of Premenstrual Syndrome," Memphis, TN, October 1992.

UTMG PMS Support Group Meeting, "Reality of PMS," Memphis, TN, August 1992.  
Annual Meeting of Memphis Area Nutrition Council, "Dietary and Drug Management of PMS," Memphis, TN, May 1992.

Department of Psychology, "Behavioral Aspects of LLPDD," Memphis State University, Memphis, TN, March 1992.

Children with Hyperactivity Disorder Syndrome (CHADS), "Medication Management of the Hyperactive Child," Memphis, TN, February 1992.

Department of Psychiatry Grand Rounds, "Leuprolide in PMS," University of Tennessee, Memphis, TN, June 1991.

Baptist East Hospital OB/GYN Noon Conference, "Research Update on Premenstrual Syndrome," Memphis, TN, January 1991.

Department of Psychiatry Grand Rounds, "Research on Natural Disasters," University of Tennessee, Memphis, TN, January 1991 (co-presented with Drs. Farmer and Cordova).

Department of Psychiatry Grand Rounds, "Research Strategies in Probing the Brain," University of Tennessee, Memphis, TN, March 1990.

Shelby County College Special Topics Group, "Differentiation Between PMS and Dysmenorrhea," Memphis, TN, March 1990.

Naval Air Station Memphis, Physician Noon Conference, "Treatment Update on PMS," Millington, TN, January 1990.

Department of Psychiatry Grand Rounds, "Research Findings in PMS," University of Tennessee, Memphis, TN, January 1990.

Research Seminar in Clinical Pharmacy, "PMS Research Findings," University of Tennessee, Memphis, TN, January 1990.

Pediatric Neuropsychiatry Seminar, "Update on Imipramine Research in ADHD," University of Tennessee, Memphis, TN, December 1989.

St. Francis Hospital Physician Noon Conference, "Management of Premenstrual Syndrome," Memphis, TN, October 1989.

Pediatric Neuropsychiatry Seminar, "Research on Attention Deficit Hyperactivity Disorder," University of Tennessee, Memphis, TN, August 1989.

Research Seminar in Clinical Pharmacy, "Use of Peripheral Serotonergic Markers in the Etiology of Premenstrual Syndrome," University of Tennessee, Memphis, TN, January 1989.

Department of Psychiatry Grand Rounds, "Etiology and Treatment of Premenstrual Syndrome," University of Tennessee, Memphis, TN, November 1988.

Psychopharmacology Workshop at Charter Lakeside Psychiatric Hospital, "Antidepressant Therapy," Memphis, TN, August 1988.

Continuing Education Workshop co-sponsored by the University of Washington Institute of Aging and the University of Washington School of Pharmacy, "Treatment of Dementia," June 1985.

Continuing Education in the Health Sciences workshop, "An Update on Psychotropic Drug Therapy," University of Alaska, Anchorage, March 1985.

Aging Together in Alaska Conference, "Seniors, Drugs and the Health Care Professional," Fairbanks, AK, August 1982.

#### **EDITORIAL APPOINTMENTS:**

Yearbook of Ob/Gyn, Sex and Sexuality, Contributing Editor, 2004-2008

Primary Psychiatry; Panel Member, 2003-2011

Annals of Pharmacotherapy, Chairperson, Women's Health Panel, 2003-Present

Annals of Pharmacotherapy, Chairperson, Psychiatry Panel, 1994-2003.

Annals of Pharmacotherapy, Psychiatry Panel Member, 1988-93.

#### **COMMITTEES AND OFFICES HELD:**

##### **Departmental Committees:**

Member, Search Committee, Research Faculty Position, Department of Clinical Pharmacy, University of Tennessee, 2012 – present.

Member, Departmental Promotion and Tenure Committee, Department of Clinical Pharmacy, University of Tennessee, 2002-present.

Member, ASPR & Disciplinary Action Committee, Department of Pharmacy, University of Tennessee, 2005-06.

Member, Departmental Promotion and Tenure Committee, Department of Pharmacy Practice and Pharmacoeconomics, University of Tennessee, 1999-02.

Member, Ambulatory Care Committee, Department of Pharmacy Practice and Pharmacoeconomics, University of Tennessee, 1998-01.

Member, Advisory Board, Department of Pharmacy Practice and Pharmacoeconomics, University of Tennessee, 1997-02.

Member, Search Committee, Ambulatory Care Faculty Position, Department of Pharmacy Practice and Pharmacoeconomics, University of Tennessee, 1997-98.

Member, Research Issues Committee, Department of Psychiatry, University of Tennessee, 1993-95.

Chairperson, PMS Research Committee, Department of Obstetrics and Gynecology, University of Tennessee, 1990-92.

Member, Research Committee, Department of Clinical Pharmacy, University of Tennessee, 1989-94.

**College and Institutional Committees:**

Member, Research Committee, 2012-2013

Member, Continuing Education, 2010-2011.

Member, Publications/Marketing/Development, 2010-2011.

Member, Facilities and Resources Committee, College of Pharmacy, University of Tennessee, 2007 – 2010.

Member, Senate, Intellectual Property Subcommittee, University of Tennessee, 2002-03.

Member, Search Committee, Faculty Position, Health Science Administration (HSA) Graduate Program, University of Tennessee, 2002-03.

Member, Search Advisory Committee, Chair, Department of Pharmacy, University of Tennessee, 2002-03.

Member, Self-Study for Accreditation – Faculty, College of Pharmacy, University of Tennessee, 2002-03.

Member, Faculty Development Committee, College of Pharmacy, University of Tennessee, 2001-02.

Member, Promotion and Tenure Committee, College of Pharmacy, University of Tennessee 1999-05.

Member, Search Committee, Chair, Pharmacy Practice & Pharmacoeconomics, College of Pharmacy, University of Tennessee, 1996-97.

Member, Continuing Education Committee, College of Pharmacy, University of Tennessee, 1995-1999, 2007-present.

Member, Search Committee, Psychiatry Pharmacy Faculty Position, College of Pharmacy, University of Tennessee, 1992-93.

Member, Honors, Awards and Scholarships Committee; College of Pharmacy, University of Tennessee, 1991-94.

Member, Task Force on Certificate Programs; College of Pharmacy, University of Tennessee, 1991-92.

Faculty Member, Concerns Obstructing Pharmacy Education (COPE) Council; College of Pharmacy, University of Tennessee, 1990-94.

#### **Grant Advisory Committees and Study Sections:**

NIH/NICHD (ZHD1 DSR-L 54 1) - Scientific Review Group, (PAR-10-190: Vulvodynia - Systematic Epidemiologic, Etiologic or Therapeutic Studies), R01 (Primary Reviewer), R21 (Primary Reviewer), R21 (Secondary Reviewer), March 2013.

NIH/NICHD (ZHD1 DSR-L VV2) - Scientific Review Group, (PAR-10-190: Vulvodynia - Systematic Epidemiologic, Etiologic or Therapeutic Studies), R01 (Secondary Reviewer), R01 (Secondary Reviewer), R01 (Discussant), R03 (Discussant), March 2012.

NIH/EMNR-Q (50) (ZRG1 - Endocrinology, Metabolism, Nutrition and Reproductive Sciences, Scientific Review Group, (RFA-OD-11-003: Specialized Centers of Research (SCOR) on Sex Differences, PO-50 (Stage 1 Reviewer), January 2012.

NIH/NICHD (ZHD1 DSR-L VV2) - Scientific Review Group, (PAR-10-190: Vulvodynia - Systematic Epidemiologic, Etiologic or Therapeutic Studies), R21 (Primary Reviewer), R03 (Secondary Reviewer), R21 (Secondary Reviewer), R01 (Discussant), February 2011.

NIH/SNEM-2 (Social Sciences, Nursing, Epidemiology and Methods-2) - Scientific Review Group, (PA-00-074: Women's Mental Health and Gender Differences Research), R01 (Primary Reviewer), July 2003.

NIH/SNEM-2 (Social Sciences, Nursing, Epidemiology and Methods-2) - Scientific Review Group, (PA-00-074: Women's Mental Health and Gender Differences Research), R01 (Primary Reviewer), October 2002.

NIH/SNEM-2 (Social Sciences, Nursing, Epidemiology and Methods-2) - Scientific Review Group, (PA-01-048: Prescription Drug Abuse), R21 (Discussant), February 2002.

NIH/SNEM-2 (Social Sciences, Nursing, Epidemiology and Methods-2) - Scientific Review Group, (PA-00-074: Women's Mental Health and Gender Differences Research), R01 (Primary Reviewer), February 2002.

NIH/SNEM-2 (Social Sciences, Nursing, Epidemiology and Methods-2) - Scientific Review Group, (PA-00-074): Women's Mental Health and Gender Differences Research), R01 (Primary Reviewer), October 2001.

### **Journal Review Assignments:**

Archives of General Psychiatry, 2010-present  
 Journal of Pain, 2009-present  
 Journal of Sexual Medicine, 2006-present  
 Journal of Women's Health, 2006-present  
 American Family Practitioner, 2007-2008  
 The Female Patient, 2006-2008.  
 Journal of Reproductive Medicine, 2004-2008  
 American Journal of Obstetrics and Gynecology, 2002-2003  
 American Journal of Managed Care, 2000-2001.  
 Obstetrics & Gynecology, 1994-96.  
 Journal of Psychosomatic Obstetrics and Gynecology, 1994-95.  
 Clinical Pharmacology & Therapeutics, 1993-95.  
 Heart & Lung, 1992-93.  
 Journal of Epilepsy, 1990-91.  
 Pharmacotherapy, 1989-93.  
 Biological Psychiatry, 1987-90.  
 Clinical Pharmacy, 1987-93.

### **National and Regional Committees and Offices:**

Reviewer, Medical Research Fund, National Vulvodynia Association (NVA), Apr, 2012

Meeting Coordinator, Vulvodynia Research Meeting, National Vulvodynia Association (NVA), Chicago, IL, 2010.

Reviewer, Medical Research Fund, National Vulvodynia Association (NVA), July, 2010.

Founding member, International Society for the Study of Premenstrual Disorders (ISSPMDS) Advisory Board, 2008-9.

Member, Continuing Education Committee, Society for the Scientific Study of Sexuality (SSSS), Allentown, PA, 2005-2006.

Member, Exhibit Committee, 38<sup>th</sup> Annual Conference, American Association of Sex Educators, Counselors, and Therapists (AASECT), New Orleans, LA, 2005-2006.

Steering Committee, Women's Health Center, UT Medical Group – Germantown, 2004.

Steering Committee, Development of Vulvar Vestibulitis Syndrome (VVS) Management Guidelines and Future Research Direction for VVS, 2004.

Content Expert Panel for Women's Health in the Pharmacy Curriculum Project, American Association of Colleges of Pharmacy (AACCP), 2003.

2001 Annual Meeting Program Committee, American College of Clinical Pharmacy (ACCP), 1999-2000.

American College of Clinical Pharmacy (ACCP), Preparatory Course Planning Committee, 1999-2001.

Program Planning Committee, College of Psychiatric and Neurologic Pharmacists (CPNP), 1998-99.

Item Writing Panel, Psychiatric Pharmacy Specialty Certification Examination, Board of Pharmaceutical Specialties (BPS), 1998-99.

Panel Member, Clinical & Therapeutic Advances in Migraine Management: A managed Care Perspective, American Journal of Managed Care (AJMC), Roundtable discussion, October 1998.

Committee on Women's Health Issues, American College of Clinical Pharmacy (ACCP); 1994-95.

Preceptor, Psychiatric Pharmacy Practice, American Society of Hospital Pharmacists (ASHP Accredited), University of Tennessee, Memphis, TN, 1992-94.

Research Committee, Psychopharmacy Special Practice Group (SPG), American Society of Hospital Pharmacists (ACCP); 1992-93.

Education Committee, Psychopharmacy Special Practice Group, American Society of Hospital Pharmacists (ASHP); 1992-93.

Task Force on the Impact of Specialization on Pharmacy Education, American Association of Colleges of Pharmacy (AACCP); 1990-91.

Psychopharmacy Program Coordinator, Midyear Clinical Meeting, American Society of Hospital Pharmacists, Atlanta, GA, 1989-90.

Public and Professional Relations Committee, American College of Clinical Pharmacy (ACCP); 1989-90.

**Consultant Appointments:**

Speakers Bureau, Hypoactive Sexual Desire Disorder (HSSD), Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 2010-2011.

Neurobiology Advisory Board, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, 2009-2011.

International Flibanserin Advisory Panel, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT. 2006-2011.

Advisory Panel on Women's Sexual Health, Johnson and Johnson Pharmaceuticals, New Brunswick, NJ. 2005-2006.

Persistent Sexual Arousal Syndrome (PSAS) Cooperative Study Group. 2005-2008.

Southeast Board on Female Sexual Health, P&G Pharmaceuticals, Inc, Mason, OH, 2004-2006.

Low Sexual Interest/Desire Disorder Advisory Panel, Solvay Pharmaceuticals, Marietta, GA, 2004-2005.

Female Sexual Dysfunction Advisory Panel, Pharmacia Corporation, Kalamazoo, MI, 2002-2003.

Consultant, Proctor and Gamble Pharmaceuticals, Mason, Ohio, 2002-2004.

Consultant, Bayer Corporation, Sexual Medicine Preceptorship Program, West Haven, CT, 2001-2003.

Speaker's Bureau, Berlex Laboratories, Inc., Wayne, NJ, 2001-2006.

Consultant, CNS Division, Visiting Faculty Program, Eli Lilly, Inc., Indianapolis, IN, 2000-2002.

Expert Panel on Evidenced-Based Management of PMS/PMDD, Berlex Laboratories, Inc., 1999-2004.

Paxil Pharmacy Advisory Board, The Medicine Group (Education) Ltd., Oxfordshire, UK, 1998-2002.

Advisory Council Member, Pfizer Behavioral Healthcare Pharmacy, New York, NY, 1998-2000.

Speakers Bureau, CNS Division, Parke-Davis and Forest Laboratories, Inc., New York, NY, 1998-2002.

Speakers Bureau, CNS Division, Visiting Faculty Program, Pfizer Roerig Pharmaceutical Group, New York, NY, 1995-1998.

Consultant, CNS Division, Visiting Faculty Program, Wyeth-Ayerst, Philadelphia, PA, 1994-96.

CNS Distinguished Faculty in Depressive Disorders, Bristol-Myers Squibb Company, Princeton, NJ, 1994-96.

Consultant, CNS Division, Visiting Faculty Program, Glaxo Smith Kline Beecham, Philadelphia, PA, 1992-1998.

Speaker's Bureau, CNS Division, Visiting Faculty Program, Bristol-Myers Squibb Company, Princeton, NJ, 1987-94.

### **RESIDENTS/FELLOWS/GRADUATE STUDENTS TRAINED:**

1. Helen Hutcherson, 1989-1993, Graduate Student, Social Psychology (M.S.) candidate, University of Memphis, Memphis, Tennessee.
2. Marshall Cates, Pharm.D, 1991-1992, Resident, Psychiatric Pharmacy Practice, University of Tennessee, Memphis, Tennessee.
3. Kim Lusk, Pharm.D, 1991-1992, Resident, Psychiatric Pharmacy Practice, University of Tennessee, Memphis, Tennessee.
4. Stephen Cooke, Pharm.D, 1992-1993, Resident, Psychiatric Pharmacy Practice, University of Tennessee, Memphis, Tennessee.
5. Clinton Wright, Pharm.D, 1992-1993, Resident, Psychiatric Pharmacy Practice, University of Tennessee, Memphis, Tennessee.
6. Sharon DeMonico, Pharm.D. 1993-1995, Fellow, Women's Mental Health, University of Tennessee, Memphis, Tennessee.
7. Nicole Parker, Pharm.D. 1998-1999, Resident, Community Practice and Women's Health, University of Tennessee, Memphis, Tennessee.
8. Nicole Parker, Pharm.D. 1999-2000, Fellow, Community Practice and Women's Health, University of Tennessee, Memphis, Tennessee.
9. Cynthia Goldsmith-Fletcher, MD. 2002-2003, Resident in Obstetrics/Gynecology, Sponsor, Research Project, "Predictors of Treatment Response in a Self-Report Survey of Vulvodynia Patients," University of Tennessee, Memphis, Tennessee.
10. Wendy Likes, 2004-2005, Doctor of Nursing Science (DNS) candidate, College of Nursing, "Validation of the Female Sexual Function Inventory in Women with Gynecologic Cancer," University of Tennessee, Memphis, Tennessee.



11. Tamra Fortenberry, MD. 2006-2007, Resident in Obstetrics/Gynecology, Sponsor, Research Project, "A Comparison of Type and Severity of Premenstrual Symptoms occurring in African American and Caucasian Women with Premenstrual Dysphoric Disorder," University of Tennessee, Memphis, Tennessee.
12. Michelle Washington, Pharm.D. 2012-2013, Fellow, Clinical Research, University of Tennessee, Memphis, Tennessee.

## **RESEARCH AND OTHER EXTERNAL SUPPORT:**

### **Research Support**

1. American Association of College of Pharmacy (AACP) Grant Program for Young Investigators, "Concentration-response Relationship of Nadolol in the Treatment of Antipsychotic-induced Akathisia." Principal Investigator: CS BROWN; Collaborating Investigator: BG Wells. \$5,000, 11/01/87 -10/31/89, Past.
2. Bristol Myers Scientific Relations Grant, "Use of Buspirone as a Pharmacologic Probe to assess Central Serotonergic Function in Premenstrual Syndrome." Principal Investigator: CS BROWN; Co-Principal Investigator: FW Ling. \$24,482, 07/01/88 - 06/30/89, Past.
3. UT Clinical Research Center, "Peripheral Measurements of Central Serotonergic Function in Premenstrual Syndrome" (5-M01-RR00211 GCRC). Principal Investigator: CS BROWN; Co-Principal Investigator: FW Ling; Collaborating Investigators: A Kitabchi, C Chesney, BG Wells. Supportive funds, 07/01/88 - 06/30/89, Past.
4. American College of Clinical Pharmacy (ACCP) Research Award in Central Nervous System Pharmacotherapy, "Concentration-Response Relationship of Imipramine in the Treatment of Attention-Deficit Hyperactivity Disorder." Principal Investigator: CS BROWN; Collaborating Investigators: JT Jabbour, BG Wells. \$5,000, 09/01/88 - 08/31/89, Past.
5. Private Industry, Multisite Study, "Double-blind, Placebo-controlled Study of the Efficacy and Safety of Low Dose BID or TID Hydrochlorothiazide for the Treatment of Fluid Retention Symptoms associated with Premenstrual Syndrome." Principal Investigator: CS BROWN; Co-Principal Investigator: FW Ling. \$40,356, 01/01/89 - 12/31/89, Past.
6. LeBonheur Children's Hospital Small Grants Program, "ADHD: Imipramine and MHPG Levels as Response Predictors." Principal Investigator: CS BROWN; Co-Principal Investigator: JT Jabbour; Collaborating Investigators: D Eastmead, B Alpert. \$7,500, 09/01/89 - 08/31/90, Past.
7. UT Clinical Research Center, "Plasma Imipramine Concentration, Urinary MHPG Concentration, and Therapeutic Response in ADHD" (5-M01-RR00211 GCRC). Principal Investigator: CS BROWN; Co-Principal Investigator: JT Jabbour; Collaborating Investigators: D Eastmead, B Alpert. Supportive funds, 09/01/89 - 08/31/90, Past.

8. UT Clinical Research Center, "Human Corticotropin-Releasing Factor in Epilepsy" (5-M01-RR00211 GCRC). Principal Investigator: CS BROWN; Co-Principal Investigator: A Wyler. Supportive funds, 01/01/89 - 12/31/91, Past.
9. Private Industry, Investigator-initiated Study, "A Placebo-Controlled Study of the Efficacy of Buspirone in the Treatment of Premenstrual Syndrome." Principal Investigator: CS BROWN; Co-Principal Investigator: F Ling. \$200,000, 07/01/89 - 06/30/92, Past.
10. UT Clinical Research Center, "Effect of Diet on Mood in Buspirone-Treated as Compared to Placebo-Treated PMS Patients" (5-M01-RR00211). Principal Investigator: CS BROWN; Co-Principal Investigator: FW Ling; Collaborating Investigator: E Lancaster. Supportive funds, 01/01/90 - 06/30/92, Past.
11. Private Industry, Investigator-initiated Study, "GnRH Agonist and the Premenstrual Syndrome." Principal Investigator: FW Ling; Co-Principal Investigator: CS BROWN. \$31,500, 07/01/90 - 06/30/92, Past.
12. Special Education Funds, Department of Obstetrics and Gynecology, University of Tennessee, "GnRH Agonist and the Premenstrual Syndrome." Principal Investigator: CS BROWN; Co-Principal Investigator: FW Ling. \$30,000, 07/01/90 - 06/30/92, Past.
13. Private Industry, Investigator-initiated Study, "Quantitation of Plasma Tryptophan/Large Neutral Amino-Acid Ratios in PMS Subjects treated with Depot Leuprolide in a Double-Blind, Placebo-Controlled Study." Principal Investigator: M Christensen; Collaborating Investigators: E Lancaster, CS BROWN, R Helms, FW Ling. \$1,000, 01/01/91 - 12/31/92, Past.
14. UT Clinical Research Center, "PMS as a Subtype of Affective Disorder" (5-M01-RR00211 GCRC). Principal Investigator: CS BROWN; Collaborating Investigators: FW Ling, RG Farmer, FB Stentz, HS Sachs. \$94,500, (Co-funded upon NIMH grant approval), grant disapproved, 05/01/91, Past.
15. Special Education Funds, Department of Obstetrics and Gynecology, University of Tennessee, "Bioimpedance Measurements in PMS." Principal Investigator: A Elsehemy; Co-Investigators: B Familoni, FW Ling, CS BROWN. \$4,700, 06/01/91 - 05/31/92, Past.
16. Special Education Funds, Department of Obstetrics and Gynecology, University of Tennessee, "Progesterone Metabolites in Premenstrual Syndrome." Principal Investigator: R Andersen; Collaborating Investigators: FW Ling, C Dass, J Kusmierz, C BROWN, DM Desiderio. \$10,000, 01/01/91 - 12/31/92, Past.
17. Private Industry, Multisite Study, "A Multicenter Randomized Double-Blind, Placebo-Controlled Comparison of Paroxetine and Fluoxetine in the Treatment of Major Depression." Principal Investigator: J Downs; Principal Investigator: CS BROWN; Collaborating Investigator: J Fowler. \$118,600, 06/01/91 - 5/31/92, Past.

18. Special Education Funds, Department of Obstetrics and Gynecology, University of Tennessee. "Fluid Shifts as a Function of the Menstrual Cycle." Principal Investigator: B Familoni; Co-Principal Investigators: FW Ling, CS BROWN. \$10,000, 07/01/91 - 06/30/92, Past.
19. Special Research Funds, Department of Psychiatry, University of Tennessee, "Incidence of Post-Traumatic Stress Disorder in Female Caretakers of Sexually Traumatized Children." Principal Investigator: RG Farmer; Collaborating Investigators: WR Veeseer, CS BROWN, D Muram. \$10,000, 07/01/91-06/30/92, Past.
20. UT Medical Group Research Grant, University of Tennessee, "PTSD in Mothers of Sexually Traumatized Children." Principal Investigator: RG Farmer; Co-Investigators: WR Veeseer, CS BROWN, B Cassinello, KL Arheart, D Muram. \$9,400, 09/01/92 - 08/31/95, Past.
21. Private Industry, Multisite Study, "Double-Blind Parallel Comparison of Sertraline and Placebo in Patients with Premenstrual Dysphoric Disorder." Principal Investigator: CS BROWN; Co-Principal Investigator: FW Ling, R Farmer. \$213,540, 01/01/93-12/31/95, Past.
22. Private Industry, Investigator-initiated Study, "Fluvoxamine in the Treatment of Major Depression with Premenstrual Worsening." Principal Investigator: CS BROWN; Co-Principal Investigator: J Downs; Collaborating Investigator: F Ling. \$39,900, 01/01/95 - 12/31/96, Past.
23. Private Industry, Multisite Study, "Outcomes and Costs of Risperidone versus Conventional Antipsychotic Therapy." Principal Investigator: LC Laizure; Collaborating Investigators: RP Johnson, M Cyr, CS Nasdahl, CS BROWN. \$120,000, 6/01/95-12/31/96, Past.
24. Private Industry, Investigator-initiated Study, "Treatment of the Premenstrual Dysphoric Disorder as a Subictal Disorder." Principal Investigator: D Blumer; Co-Principal Investigators: C BROWN, FW Ling. \$20,000, 1/01/96 - 12/31/96, Past.
25. Pfizer Scientific Relations Grant, "Sertraline Concentration - Response Relationships in Women with Premenstrual Dysphoric Disorder according to the Menstrual Phase." Principal Investigator: CS BROWN, Collaborating Investigator: M Meyer, \$11,000, 7/1/96 - 6/30/97, Past.
26. Private Industry, Multisite Study, "Double-Blind Parallel Comparison of Luteal Phase Dosing of Sertraline and Placebo in Patients with Premenstrual Dysphoric Disorder." Principal Investigator: CS BROWN, Co-Principal Investigator: F Ling. \$278,000 6/01/96 - 5/31/99, Past.
27. UT Medical Group Research Grant, University of Tennessee, "Effect of Providing Individual Family Therapy To Borderline Personality Disorder Patient." Principal Investigator: D Allen, Co-Investigator: RG Farmer, CS BROWN, \$10,000, 7/1/96-6/30/99, Past.

28. Private Industry, Multisite Study, "A Double - Blind Comparison of Fixed Dose Sertraline and Placebo for the Treatment of Premenstrual Syndrome." Principal Investigator: CS BROWN, Collaborating Investigators: FW Ling, D Allen, \$132,700, 2/1/97 - 1/31/99, Past.
29. Private Industry, Investigator-initiated Study, "Luteal Phase Dosing of Sertraline in Oral Contraceptive and Non - Oral Contraceptive Users," Principal Investigator: CS BROWN, Collaborating Investigator: FW Ling. \$58,800, 4/1/97 - 3/31/99, Past.
30. Private Industry, Multisite Study, "Multicenter, Double-Blind, Randomized, Placebo Controlled, Parallel Group Study To Evaluate Efficacy Of A Monophasic Oral Contraceptive Preparation, Containing Drospirenone 3 mg and Ethinyl Estradiol 30 mcg in the Treatment of Premenstrual Syndrome." Principal Investigator: CS BROWN, Collaborating Investigator: FW Ling, \$96,000, 8/31/97 - 7/31/99, Past.
31. Private Industry, Multisite Study, "Factor Analysis, Discriminant Validity and Test-Retest Reliability of a Self-Report Measure of Female Sexual Function in Women with Sexual Dysfunction." Principal Investigator: CS BROWN, Collaborating Investigators: TG Stovall, JY Wan. \$26,500, 3/1/99 - 2/28/00, Past.
32. Private Industry, Multisite Study, "Validation of the Calendar of Premenstrual Experience (COPE)." Principal Investigator: CS BROWN, Collaborating Investigator: FW Ling, \$34,400, 6/1/99-5/30/00, past.
33. Center for Women's Health Improvement, University of Tennessee. "Efficacy of Static Magnetic Field Therapy in Chronic Pelvic Pain." Principal Investigator: CS BROWN, Collaborating Investigators: FW Ling, B Familoni, JY Wan, \$25,000, 7/01/99-6/30/00, past.
34. Private Industry, Investigator-initiated Study, "Efficacy of Static Magnetic Field in Chronic Pelvic Pain." Principal Investigator: CS BROWN, Collaborating Investigators: FW Ling, B Familoni, JY Wan, \$25,000, 7/1/99 - 6/30/00, past.
35. Private Industry, Investigator-initiated Study, "Open Label Trial of Citalopram in the Treatment of Women with Chronic Pelvic Pain." Principal Investigator: CS BROWN, Collaborating Investigators: FW Ling, LD Wade, JY Wan, \$74,920, 9/1/99 - 8/31/02, past.
36. Private Industry, Investigator-initiated Study, "Comparison of the Pharmacokinetic and Safety Profile of Sublingual, Buccal and Subcutaneous Apomorphine in Women with a Sexual Dysfunction." Principal Investigator: CS BROWN, Collaborating Investigators: FW Ling, JY Wan. \$163,437, 10/1/99 - 9/30/00, past.
37. Private Industry, Multisite Study, "Factor Analysis, Discriminant Validity and Test-Retest Reliability of a Self-Report Measure of Female Sexual Function in Postmenopausal Women with Sexual Dysfunction." Principal Investigator: CS BROWN, Collaborating Investigator: TG Stovall, \$10,060, 10/01/99 - 09/30/00, past.

38. Private Industry, Multisite Study, "Double-Blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of Paroxetine in Premenstrual Dysphoric Disorder." Principal Investigator: FW Ling, Co-Principal Investigator: CS BROWN, \$103,560, 10/01/99 - 09/30/02, past.
39. Private Industry, Multisite Study, "Validation of a Self-Report Measure of Hysterectomized Women with Sexual Dysfunction compared to Non-Hysterectomized Controls without Sexual Dysfunction." Principal Investigator: CS BROWN, Collaborating Investigator: TG Stovall, \$21,306, 1/01/00 - 12/31/00, past.
40. Private Industry, Investigator-initiated Study, "A Double-Blind, Placebo-Controlled Study of Creatine-Pyruvate (3.5 g and 5.25 g/day) for Premenstrual Syndrome." Principal Investigator: CS BROWN, Collaborating Investigators: FW Ling, RB Kreider, \$24,133, 1/01/00 - 6/30/01, past.
41. Private Industry, Multisite Study, "A Phase 2 Study of the Use of PH80 for Management of the Symptoms of Clinically Significant Premenstrual Syndrome (PMS): #PH80 CL015." Principal Investigator: CS BROWN, Collaborating Investigators: FW Ling, T Elmore, \$86,400, 1/01/01 - 12/31/02, past.
42. Private Industry, Multisite Study, "A 3-month, Double-Blind, Placebo-Controlled, Fixed Dose, Extension Study of Paroxetine CR (12.5 mg and 25 mg/day), Continuous Treatment for PMDD Patients Completing Study 29060/677." Principal Investigator: CS BROWN, Collaborating Investigators: FW Ling, T Elmore, \$52,200, 1/01/01 - 12/31/02, past.
43. Private Industry, Multisite Study, "A Multicenter, Double-Blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of a Monophasic Oral Contraceptive Preparation Containing Drospirenone 3 mg, Ethinyl Estradiol 20 mcg (as Beta-Cyclodextrin Clathrate), in the Treatment of Premenstrual Dysphoric Disorder (PMDD)." Principal Investigator: CS BROWN, Collaborating Investigators: FW Ling, T Elmore, \$74,040, 2/01/01 - 1/31/04, past.
44. Private Industry, Multisite Study, "A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Study of the Efficacy and Safety of Femprox™ Cream in Premenopausal Patients with Female Sexual Arousal Disorder." Principal Investigator: CS BROWN, Collaborating Investigator: I Anand, \$39,120, 7/01/01 - 6/30/02, past.
45. Private Industry, Multisite Study, "Preliminary Efficacy Study in Pre-menopausal Women with Normal or Impaired Sexual Function Due to Acquired Arousal and/or Orgasm Disorder Comparing PNU-142774E 1.0-mg to Placebo: Double-Blind with 8-Week Home Treatment Phase." Principal Investigator: CS BROWN, Collaborating Investigator: I Anand, J Norwood, \$30,288, 8/01/01 - 7/31/02, past.
46. Private Industry, Investigator-initiated Study, "An Open Label Trial of Botulinum Toxin Type A in the Treatment of Women with Vulvar Vestibulitis Syndrome." Principal Investigator: CS BROWN, Collaborating Investigators: V Vogt, D Menkes, F Ling, \$69,000, disapproved 4/01/03, past.

47. Research Institute of the American College of Clinical Pharmacy, Career Development Research Award, "Botulinum Toxin Type A in Women with Vulvar Vestibulitis Syndrome," Principal Investigator: CS BROWN, Collaborating Investigators: V Vogt, D Menkes, F Ling, \$55,000, disapproved, 5/8/03, past.
48. Private Industry, Multisite Study, "A Phase-III, Multinational, Randomized, Double-blind, Parallel Group, Placebo-Controlled 24-Week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone in Women with Low Libido who have Undergone Hysterectomy and Bilateral Oophorectomy on Concurrent Estrogen Replacement Therapy." Principal Investigator: CS BROWN, Collaborating Investigator: I Anand, \$54,240, 6/01/02 – 5/30/04, past.
49. Private Industry, Multisite Study, "A Phase III, Multinational, Randomized, Double-blind, Parallel Group, Placebo-Controlled One-Year Study to Evaluate the Efficacy and Safety of Transdermal Testosterone in Naturally Menopausal Women with Low Libido on Concurrent Oral Hormone Replacement Therapy." Principal Investigator: CS BROWN, Collaborating Investigator: I Anand, \$54,240, 6/01/02 – 5/30/04, past.
50. Department of Obstetrics, Gynecology and Reproductive Sciences, Robert Wood Johnson Medical School, UMDNJ, New Brunswick, NJ, "Effects of the Menstrual Cycle on Symptoms in Women with Vulvodynia," Principal Investigator: Dilek Avci, Collaborating Investigators: C BROWN, G Bachmann, Departmental Funds, 5/01/04 – 2/01/05, past.
51. A Randomized, Double-blind, Placebo-controlled, Comparative Study of the Efficacy of Botulinum Toxin Type A in the Treatment of Women with Vulvar Vestibulitis Syndrome. National Vulvodynia Association (NVA) Research Proposal, Principal Investigator: CS BROWN, Collaborating Investigators: Gloria Bachmann, Howard Glazer, \$24,978, 9/1/04, Denied.
52. Private Industry, "An Open Label Trial of Botulinum Toxin Type A in the Treatment of Women with Vulvar Vestibulitis Syndrome." Principal Investigator: CS BROWN, Collaborating Investigators: G Bachmann, A Nieves, H Glazer, Robert Wood Johnson Medical School, UMDNJ, New Brunswick, NJ, \$9,000, 5/1/04 – 4/30/05, past.
53. NICHD (National Institute of Child Health and Human Development), "Vulvodynia Prevalence and Efficacy of 4 Interventions." (5R01HD040119-02). Principal Investigator, G Bachmann, Collaborating Investigators: RC Rosen, SR Leiblum, L Arnold, CS BROWN, \$1,373,750.00, 9/29/00 – 8/31/05, past.
54. Private Industry, Multisite Study, "A Phase-III, Multinational, Open Label, 24-Week Study to Evaluate the Safety of Transdermal Testosterone in Women with Low Libido who have Undergone Hysterectomy and Bilateral Oophorectomy on Concurrent Estrogen Replacement Therapy." Principal Investigator: CS BROWN, Collaborating Investigator: I Anand, \$17,676, 6/01/02 – 5/30/06, past.

55. UT Clinical Research Center, "An Open Label Trial of Botulinum Toxin Type A in the Treatment of Women with Vulvar Vestibulitis Syndrome." (GCRC #746). Principal Investigator: CS BROWN, Collaborating Investigators: R Wiygul, D Menkes, F Ling, J Wan, \$14,550, 5/01/03 – 11/01/05, past
56. Private Industry, Investigator-initiated Study, "Open Label Trial of Escitalopram in the Treatment of Women with Chronic Pelvic Pain." Principal Investigator: CS BROWN, Collaborating Investigators: FW Ling, JY Wan, \$74,920, 1/1/04 - 12/31/06, past.
57. Department of Psychiatry, University Behavioral Health Care, Robert Wood Johnson Medical School, UMDNJ, Piscataway, NJ, "A Questionnaire Survey of Female Persistent Sexual Arousal," Principal Investigator: S Leiblum, Collaborating investigator: CS BROWN, Departmental Funds, 1/1/04 – 12/31/06, past.
58. Private Industry, Multisite Study, "A randomized double-blind placebo-controlled parallel-group multicenter 52-week study to evaluate the efficacy and safety of transdermal patches delivering 150 mcg or 300 mcg per day testosterone in menopausal women with low libido not receiving systemic estrogen or estrogen-progestin therapy," Principal Investigator: CS BROWN, Collaborating Investigator: M Summitt, \$54,240, 7/01/04 – 6/30/06, past.
59. Investigator-initiated Study, "A Comparative Evaluation of Sexual Functioning in Women with Vulvodynia and Women with Healthy Sexual Function using a Patient-Rated Questionnaire," Principal Investigator: CS BROWN, Collaborating Investigators: R Masheb, G Bachmann, J Wan, R Rosen, Departmental Funds, 5/01/05 – 6/30/06, past.
60. Investigator-initiated Study, "A Comparative Evaluation of Sexual Functioning in Women with Persistent Sexual Arousal Syndrome (PSAS), Women with Female Sexual Arousal Disorder (FSAD), and Women with Healthy Sexual Function Using a Patient-Rated Questionnaire," Principal Investigator: CS BROWN, Collaborating Investigators: S Leiblum, M Wiegel, J Wan, R Rosen, Departmental Funds, 5/01/05 – 6/30/06, past.
61. Investigator-initiated Study, "A Comparative Evaluation of Sexual Functioning in Women Vulvodynia, Women with Intraepithelial Carcinoma (VIN) and Women with Healthy Sexual Function using a Patient-Rated Questionnaire," Principal Investigator: W Likes, Collaborating Investigators: CS BROWN, R Masheb, G Bachmann, J Wan, M Wiegel, R Rosen, Departmental Funds, 5/01/05 – 6/30/06, past.
62. UT Clinical Research Center, "A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Botulinum Toxin Type A in the Treatment of Women with Vestibulodynia." Principal Investigator: CS BROWN, Collaborating Investigators: V Vogt, H Glazer, D Menkes, J Wan, 11/01/05 – 10/31/07, past.
63. Private Industry, Multisite Study, "A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of PT-141 in the Treatment of Female Sexual Arousal Disorder." Principal Investigator: CS BROWN, Collaborating Investigator: Frank Ling, \$39,720, 1/1/06 – 6/30/07, past.

64. American College of Obstetricians and Gynecologists (ACOG)/Berlex, Inc. Research Award in PMS/PMDD, "A Comparison of Type and Severity of Premenstrual Symptoms occurring in African American and Caucasian Women with Premenstrual Dysphoric Disorder." Principal Investigator: Tamra Fortenberry, Collaborating Investigators: CS BROWN, Frank Ling, \$25,000, 2/1/06 – 1/31/07, past.
65. Private Industry, Multisite Study, "A Six-Month, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Trial of Flibanserin in Female Patients with Hypoactive Sexual Desire Disorder in North America." Principal Investigator: T Stovall, Collaborating Investigator: CS BROWN, F Ling, K Weinberg, \$142,884, 7/1/06 – 6/30/08, past.
66. Private Industry, Multisite Study, "Discriminant Validation of the Inventory for Sexual Events and Desire and the Desire Domain on the Sexual Function Questionnaire." Principal Investigator: CS BROWN, Collaborating Investigator: F Ling, \$29,160, 12/1/06 – 11/30/07, past.
67. National Vulvodynia Association, "Pilot Study to Create Electronic Medical Database Specifically Designed to Capture Select Vulvodynia Data," Principal Investigator: M Kilibwa, Collaborating Investigators: CS BROWN, G Bachmann, P Richey, F Ling, J Wan, \$5,000, 3/1/07, denied.
68. National Institute of Health (K 23). Patient Oriented Research Award, "Predictors of Sexual Function and Quality of Life Following Vulvar Excision. Principal Investigator: WM Likes, Consultant: C BROWN, 3/1/06-2/28/09, past.
69. Private Industry, Multisite Study, "A Twelve Month, Open Label Safety Trial of Flibanserin 50 mg to 100 mg Daily in Women with Hypoactive Sexual Desire Disorder." Principal Investigator: Thomas Stovall, Co-Investigators: CS BROWN, F Ling, K Weinberg, \$160,010, 5/1/07 – 4/30/09, past.
70. Private Industry, Multisite Study, "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Libigel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women," Principal Investigator: CS BROWN, Co-Investigators: F Ling, T Stovall, \$72,576, 5/1/07 – 4/30/10, past.
71. American College of Clinical Pharmacy (ACCP) Frontiers Career Development Research Award, "Drug Treatment Protocol for Vulvodynia using an Innovative Delivery System," Principal Investigator: CS BROWN, Collaborating Investigators: G Bachmann, F Ling, P Richey, J Wan, \$22,380, 6/1/07, denied.
72. National Institute of Health. Patient Oriented Research Award (K 23), "Predictors of Sexual Function and Quality of Life Following Vulvar Excision. "Principal Investigator: WM Likes, CS Expert mentors: D Hathaway, B Reed, H Haefner, Consultants: C BROWN, C Stegbauer, T Tillmanns, \$100,000, 7/1/07 – 6/30/10, past.



73. Private Industry, Multisite Study, "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women," Principal Investigator: CS BROWN, Co-Investigators: F Ling, T Stovall, \$124,056, 4/1/08 – 3/31/12, past.
74. National Vulvodynia Association, "Self-Management Program for Women with PVD," Principal Investigator: C BROWN, Collaborating Investigators: CS BROWN, J Mohl, J Wan, G Bachmann, F Ling, J Wan, \$24,950, 8/15/08, denied.
75. Private Industry, Multisite Study, "HSDD in Women Registry," Principal Investigator: CS BROWN, Co-Investigators: F Ling, \$395,640, 7/1/08 – 11/30/10, past.
76. Private Industry, Investigator-Initiated Study, "An Evaluation of Liquibeads in the Treatment of Acquired Dyspareunia and the Effect on Sexual Intercourse Discomfort and Patient Satisfaction in Postmenopausal Women, Principal Investigator: CS BROWN, Co-Investigators: S Leiblum, J Bradford, J Wan, \$43,724, 7/1/08 – 6/30/10, past.
77. Private Industry, Investigator-Initiated Study, "Effect of Erectile Dysfunction and its Treatment on Women with a Female Sexual Disorder: Reliability and Validity of a Screening Instrument, Principal Investigator: CS BROWN, \$74,640, 2/15/09, denied.
78. Recovery Act Limited Competition: NIH Challenge Grants in Health and Science Research (RC1), National Institute of Child Health & Human Development (NICHD), "Controlled Trial of Gabapentin in Vulvodynia: Biological Correlates of Response," Consortium: Principal Investigators: C BROWN, G Bachmann, D Foster, Co-Investigators: F Ling, R Dworkin, C McDonald, J Wan, B Meibolm, L Thoma, \$999,856, 4/10/09, denied.
79. UT Clinical and Translational Science Institute (CTSI) Pilot Project Grant, "A Prospective Trial of Gabapentin in Vulvodynia: Biological Correlates of Responses," Consortium: Principal Investigators: C BROWN, G Bachmann, D Foster, Co-Investigators: F Ling, R Dworkin, C McDonald, J Wan, \$99,982, 6/01/09, denied.
80. National Institute of Health R01, National Institute of Child Health & Human Development (NICHD), "Efficacy of Single and Combined Therapy in Women with Provoked Vestibulodynia (P 07-182), Consortium: Principal Investigators: C BROWN, G Bachmann, D Foster, Co-Investigators: F Ling, R Dworkin, C McDonald, J Wan, B Meibolm, L Thoma, \$3,558,927, 4/01/10, denied.
81. NIH Scientific Conference/Meeting Grant (R13), National Institute of Child Health & Human Development (NICHD), "International Conference on the Development and Measurement of Clinical Outcomes in Vulvodynia": Consortium: Principal Investigators: C BROWN, G Bachmann, D Foster in sponsorship with National Vulvodynia Association, \$45,730, 4/01/102/09, denied.

82. Private Industry, Multisite Study, "A Twenty-Four Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Trial of Flibanserin 100 mg daily in Postmenopausal Women with Hypoactive Sexual Desire Disorder in North America (511.156)." Principal Investigator: C BROWN, Collaborating investigators: TS Stovall, F Ling, \$114, 592, 3/1/10 – 11/30/10, past.
83. Private Industry, Multisite Study, "A Twelve Month, Open-Label Safety Trial of Flibanserin 100 mg daily in Postmenopausal Women with Hypoactive Sexual Desire Disorder in North America." Principal Investigator: C BROWN, Collaborating investigators: TS Stovall, F Ling, \$105,780, 4/1/10 – 11/30/10, past.
84. Private Industry, Investigator-Initiated Study. "An Open Label Trial of Milnacipran in the Treatment of Women with Provoked Vestibulodynia." Principle Investigator: C BROWN, Collaborating Investigators: F Ling, J Wan, \$149,296, 3/10/10 – 2/28/13, past.
85. National Institute of Health R01, National Institute of Child Health & Human Development (NICHD) and Office of Research for Women's Health (ORWH). "A controlled trial of gabapentin in vulvodynia: Biological correlates of response. (P 07-182), Consortium: Principal Investigators: C BROWN, G Bachmann, D Foster, Co-Investigators: F Ling, R Dworkin, C McDonald, J Wan, L Thoma, \$2,809,589, 3/1/11 – 2/28/15.
86. National Vulvodynia Association (NVA), "Development of a Vulvodynia Center of Excellence." Principal Investigator: CS BROWN, Co-investigator: F Ling, J Wan, \$22,500, 5/01/11 – denied.
87. Private Industry, Multisite Study, "A Placebo-controlled, Randomized, Parallel Group, Dose-finding Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with FSAD and/or HSDD." Principal Investigator, CS BROWN, \$77,784, 6/1/11 – 5/30/13 (withdrawn due to time constraints).
88. UT Clinical Research Center, "A Controlled Trial of Gabapentin in Vulvodynia: Biological Correlates of Response – Substudy" (10-00985-FB, CRC #821). Principal Investigator: CS BROWN; Collaborating Investigators: Thorpe E, Ling F, McDonald C, Wan J, Thoma L, Ramsey R, 02/01/12 – 01/31/13, past.
89. UT Clinical Research Center, "A controlled trial of gabapentin in vulvodynia: Biological correlates of response." (CRC #822), Principal Investigators: C BROWN, Collaborating Investigators: Thorpe E, Ling F, McDonald C, Wan J, Thoma L, Ramsey R, 2/01/12 – 1/31/14.
90. UT College of Pharmacy Research Equipment Proposal, "Development of an electronic Visual Analogue Thermometer for the measurement of pain intensity in clinical trials," \$15,000, 05/01/12 – 4/30/13 – denied.

### External Support

1. Department of Mental Health and Mental Retardation (MHMR), Memphis Mental Health Institute (MMHI) Clinical Pharmacy Services Contract No. 3593. \$60,000, 07/01/92 - 06/30/94, Past.
2. College of Pharmacy, Specialty Residency in Community Practice and Women's Health, \$12,500, 07/01/98-06/30/99.
3. University of Tennessee Medical Group, Department of Obstetrics and Gynecology, Gynecologic Division, Provider, Annual Planned Income (API). 07/01/99 - 06/30/05.

### BOOKS AND BOOK CHAPTERS:

1. Bryant SG, BROWN CS. Major depressive disorders. In: Young, Koda-Kimble, Guglielmo, and Kradjan (Eds.). Handbook of Applied Therapeutics, Vancouver, WA: Applied Therapeutics, Inc., 1989, pp 102-9.
2. Bryant SG, BROWN CS. Major depression. In: Koda-Kimble and Young (eds.), Applied Therapeutics: The Clinical Use of Drugs, 4th Ed, Spokane, WA: Applied Therapeutics, Inc., 1989, pp 50.1-50.11.
3. BROWN CS, Bryant SG. Major depression. In: Koda-Kimble, Young, Kradjan, and Guglielmo (eds.), Applied Therapeutics: The Clinical Use of Drugs, 5th Ed, Spokane, WA: Applied Therapeutics, Inc., 1992, pp, 57.1 - 57.18.
4. BROWN CS, Bryant SG. Major depressive disorders. In: Koda-Kimble, Young, Kradjan, and Guglielmo (eds.), Handbook of Applied Therapeutics. 2nd Ed. Vancouver, WA: Applied Therapeutics, Inc., 1992, pp 55.1 - 55.12.
5. BROWN CS. Reactions to antidepressants: Monoamine oxidase inhibitors. In: Tornatore and Sramek (Eds.). Psychotropic Medications: A Desktop Reference for Mental Health Practitioners. Providence, RI: Manisses Communication Group, Inc, 1996, pp 137-46.
6. Guthrie S, BROWN CS, Cyr M. Reactions to antidepressants: Cyclics, SSRIs, Miscellaneous. In: Tornatore and Sramek (Eds.). Psychotropic Medications: A Desktop Reference for Mental Health Practitioners. Providence, RI: Manisses Communication Group, Inc., 1996, pp 63-137.
7. Cyr M, BROWN CS. Current drug therapy recommendations for the treatment of attention deficit hyperactivity Disorder. In: KJ Palmer (Ed). Topics in Paediatric Psychiatry. Hong Kong, China: Adis International Ltd, 2000, pp 69-79.

8. BROWN CS, Ling FW. Sex and Sexuality in Pregnancy. In JJ Sciarra (Ed.). Gynecology & Obstetrics. Vol 2, Chapter 20. Philadelphia, PA: Lippincott, Williams & Wilkins, 2001, pp 1-9.
9. BROWN CS, Ling FW. Premenstrual Syndrome. In: Ling F and Duff (Eds.). Obstetrics and Gynecology: Principles for Practice. New York, NY: McGraw-Hill, 2001, pp 1004-1020.
10. BROWN CS, Ling FW, Kuntz TB. Premenstrual Syndrome. In: Ling F and Duff (Eds.). Obstetrics and Gynecology: Principles for Practice (Pocket Guide). New York, NY: McGraw-Hill, 2002, pp 735-743.
11. BROWN CS. Women's Health (Chapter 15). In: Gourley D and Eoff J, Eds.). APhA's Complete Review for Pharmacy, 3<sup>rd</sup> Ed. New York, NY: Castle Connolly Graduate Medical Publishing Ltd, 2005, pp 315-333.
12. C BROWN. Sexuality (Chapter 35), In: Schulman LP (Ed). Year Book of Obstetrics, Gynecology, and Women's Health. Philadelphia, PA: Elsevier Mosby, 2005, pp: 497-506.
13. BROWN CS, Ling FW. Premenstrual Syndrome/Premenstrual Dysphoric Disorder (Chapter 2). In: Bieber, San Fillipo, and Horowitz: Clinical Gynecology. Philadelphia, PA: Elsevier, Inc, 2005, pp 19-36.
14. Patel M, BROWN CS, Bachmann G. Sexual function in the menopause and perimenopause. In: Goldstein I, Meston C, Davis S, and Traish (Eds.). Women's Sexual Function and Dysfunction: Study, Diagnosis and Treatment. Oxfordshire, England: Taylor & Francis Medical, 2006, pp 251-262.
15. BROWN CS, Ling F. Hormonal Therapies Overview. In: O'Brien PMS, Rapkin AJ & Schmidt PJ: The Premenstrual Syndromes: PMS and PMDD. Abingdon, UK: Informa Healthcare, 2007, pp 109-166.
16. BROWN C. Sexuality (Chapter 22), In: Schulman LP (Ed). Year Book of Obstetrics, Gynecology, and Women's Health. Philadelphia, PA: Elsevier Mosby, 2007, pp: 197-210.
17. BROWN CS. Sexual Dysfunction in Women. In Stovall T, Ling F, Zite et al (Ed). Gynecology for the Primary Care Physician, 2<sup>nd</sup> Edition. Philadelphia, PA: Springer Science+Business Media LLC, New York, NY, 2008, pp 387-392.
18. BROWN CS, Ling FW. Women's Health (Chapter 20), In: Lee M (Ed). Basic Skills in Interpreting Laboratory Data, 4th Ed., American Society of Health System Pharmacists (ASHP), Washington, DC, 2009, pp 525-540.

19. BROWN CS. Sexual Dysfunction (Chapter 12-P34). In: Olson R (Ed). Women's Primary Health Care. 2<sup>nd</sup> Ed., American Society of Health System Pharmacists (ASHP), Washington. DC, 2009, pp 12.132-12.145.
20. BROWN CS, Bradford J, Ling FW. Sex and Sexuality in Pregnancy. In JJ Sciarra (Ed.). Gynecology & Obstetrics. Vol 2, Chapter 20. Philadelphia, PA: Lippincott, Williams & Wilkins, 2009.
21. BROWN CS. Sexuality and Sexual Issues (Chapter 26), In: Alexander I, Hood, Johnson-Mallard, Kostas-Polston EA (Eds). Comprehensive Women's Health Care. St. Louis, MO: Mosby Inc., 2010.
22. BROWN CS, Leiblum SR (Chapter 35). Sexual Disorders. In: Borgelt LM et al (Eds). Women's Health Across the Lifespan. American Society of Health-System Pharmacists (ASHP), Washington, DC, 2010, pp 545-562
23. Washington MJ, BROWN CS, Ling FW. Premenstrual Syndrome/Premenstrual Dysphoric Disorder (Chapter 2). In: E Bieber, J San Filippo, I Horowitz, and MI Shafi: Clinical Gynecology, 2<sup>nd</sup> Ed, Cambridge: Cambridge University Press, 2013, pp.
24. Washington MJ, BROWN CS. Women's Health (Chapter 20), In: Lee M (Ed). Basic Skills in Interpreting Laboratory Data, 5th Ed., Bethesda, MD: American Society of Health System Pharmacists; 2013.

#### **PEER-REVIEWED JOURNAL ARTICLES:**

1. Bryant SG, BROWN CS. Current concepts in clinical therapeutics: Major affective disorders, Part 1. Clinical Pharmacy, 1986;5:304-18.
2. Bryant SG, BROWN CS. Current concepts in clinical therapeutics: Major affective disorders, Part 2. Clinical Pharmacy, 1986;5:353-95.
3. BROWN CS, Wittowsky AK, Bryant SG. Neuroleptic-induced catatonia following abrupt withdrawal of amantadine during neuroleptic therapy. Pharmacotherapy, 1986;6(4):32-5.
4. BROWN CS, Bauer LA, Horn JR. Phenytoin removal by plasmapheresis in renal insufficiency. American Journal of Nephrology, 1986;6:302-6.
5. Bryant SG, BROWN CS. Pharmacists' perceptions of mentally-ill patients. American Journal of Hospital Pharmacy, 1986;43:312 (Letter).
6. BROWN CS, Wright RG, Christensen DB. Association between type of medication instruction and patients' knowledge, side effects, and compliance. Hospital and Community Psychiatry, 1987;38:55-60.

7. Boggs P, BROWN CS, DeLapp T. Nurses' drug knowledge. Western Journal of Nursing Research, 1988;10:84-93.
8. BROWN CS, Solovitz BL, Bryant SG, Guernsey GG, Fisher S. Short and long-term effects of auxiliary labels on patient knowledge of precautionary drug information. Drug Intelligence and Clinical Pharmacy, 1988;22:470-3.
9. Kent TA, BROWN CS, Bryant SG, Barratt ES, Felthous AR, Rose RM. Blood platelet serotonin in episodic aggression: Correlation with red blood cell proton T<sub>1</sub> and impulsivity. Psychopharmacology Bulletin, 1988;24:454-7.
10. BROWN CS, Bryant SG. Monoamine oxidase inhibitors: Safety and efficacy issues. Drug Intelligence and Clinical Pharmacy, 1988;22:232-5.
11. Wells BG, Marken PA, Rickman LA, BROWN CS, Hamann G, Grimmig J. Characterizing anticholinergic abuse in community mental health. Journal of Clinical Psychopharmacology, 1989;9:431-5.
12. Marken PA, Wells BG, BROWN CS. Treatment of psychosis in pregnancy. Drug Intelligence and Clinical Pharmacy, 1989;23:598-9.
13. BROWN CS, Taniguchi G, Yip K. The monoamine oxidase inhibitor tyramine interaction. Journal of Clinical Pharmacology, 1989;29:529-32.
14. BROWN CS, Bryant SG, Gevedon RM, Felthous AR, Rose RM, Barratt ES, Kent TA. Blood platelet uptake of serotonin in episodic aggression. Psychiatry Research, 1989;27:5-12.
15. Sitland-Marken PA, Wells BG, Froemming JH, Chung-Chou C, BROWN CS. Psychiatric applications of bromocriptine therapy. Journal of Clinical Psychiatry, 1990;51:68-82.
16. BROWN CS, Bryant SG. Drug treatment of depression. Journal of Pharmacy Practice, 1990; 3:252-61.
17. BROWN CS, Cold J, Wells BG, Self G, Jabbour JT. Influence of carbamazepine on plasma imipramine concentrations in children with attention-deficit hyperactivity disorder. Journal of Clinical Psychopharmacology, 1990;5:1-5.
18. Bryant SG, BROWN CS, Hokanson JA. Trazodone prescribing patterns for depressed inpatients. Journal of Clinical Psychiatry, 1990;51 (Suppl. 9):27-29.

19. Wells BG, Cold JA, Marken PA, BROWN CS, Chung-Chou C, Johnson RP, Nasdahl CS, Ayubi MA, Knott DH, Arheart KL. A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia. Journal of Clinical Psychiatry, 1991;52(6):255-60
20. BROWN CS, Rakel RE, Wells BG, Downs J, Akiskal H. A practical update on anxiety disorders and their clinical pharmacology. Archives of Internal Medicine, 1991;151(5):873-84.
21. BROWN CS. Treatment of attention deficit hyperactivity disorder: A critical review. DICP Annals of Pharmacotherapy, 1991;25:1207-1213.
22. BROWN CS. Relationship between ADHD and diet. DICP Annals of Pharmacotherapy, 1992; April 1992 (Letter).
23. BROWN CS. Premenstrual syndrome: Issues in pharmacotherapy. The ACCP Report 1992; November.
24. BROWN CS, Cooke SC. Attention deficit hyperactivity disorder: Clinical features and treatment options. CNS Drugs, 1994;1(2):95-106.
25. BROWN CS, Ling FW, Andersen RN, Farmer RG, Arheart KL. Efficacy of depot leuprolide in premenstrual syndrome: Effect of symptom severity and type in a controlled trial. Obstetrics & Gynecology, 1994;84:779-86.
26. DeMonico SO, BROWN CS, Ling FW. Premenstrual syndrome. Current Opinion in Obstetrics and Gynecology, 1994;6:499-502.
27. DeMonico SO, BROWN CS, Ling FW. Premenstrual syndrome: Helping women cope with cyclic physical and emotional upheaval. Consultations in Primary Care, 1995;July:994-1006.
28. Yonkers KA, Halbreich U, Freeman EW, BROWN CS, Pearlstein TB. Efficacy of sertraline for the treatment of premenstrual dysphoric disorder. Psychopharmacology Bulletin, 1996; 32 (1):4-6.
29. Cyr M, BROWN CS. Nefazodone. Nefazodone: Its place among antidepressants Annals of Pharmacotherapy, 1996;30(9):1006-1011.
30. Yonkers KA, Halbreich U, Freeman E, BROWN CS, Endicott J, Frank E, Parry D. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. Journal of the American Medical Association, 1997: 278 (12):983-988.

31. BROWN CS. An update on the treatment of premenstrual syndrome. American Journal of Managed Care, 1998;4(2):115-124.
32. Cyr M, BROWN CS. Current drug therapy recommendations for the treatment of attention deficit hyperactivity. Drugs, 1998;56(3):1-10.
33. Woodrum S, BROWN CS. Selective serotonergic reuptake inhibitors (SSRI) - induced sexual dysfunction. Annals of Pharmacotherapy, 1998;32:1209-15.
34. Yonkers KA, Halbreich U, BROWN CS, et al. Sertraline for premenstrual dysphoric disorder. Letter to Editor: Reply to Dr. Cohen. Journal of the American Medical Association, 1998 (Letter);279(5):358.
35. Markowitz JS, BROWN CS, Moore TR. A critical review of the atypical antipsychotics, Part 1. Annals of Pharmacotherapy, 1999;33:73-85.
36. BROWN CS, Markowitz JS, Moore TR, Parker, NG. A critical review of the atypical antipsychotics, Part 2. Annals of Pharmacotherapy, 1999;33(2):210-7.
37. BROWN CS, Parker NG, Stegbauer C. Considerations in the management of allergic rhinitis for the nurse practitioner. Nurse Practitioner, 1999;24(6): 2-8.
38. BROWN CS, Ling FW. Significant Advances in the Management of PMS (1989-1999). OBG Management: 1999; October:11-29.
39. Pearlstein T, Halbreich U, Batzar ED, BROWN CS, Endicott J, Frank E, Freeman EW, Harrison WM, Haskett RF, Stout AL, Yonkers KA. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. Journal of Clinical Psychiatry, 2000;61(2):101-109.
40. Parker NG, BROWN CS. Citalopram in the Treatment of Depression. Annals of Pharmacotherapy, 2000;34(6):761-771.
41. Rosen R, BROWN C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D. The FSDQ: A multidimensional self-report instrument for the assessment of female sexual dysfunction. Journal of Sex and Marital Therapy, 2000;26(2):191-208.
42. BROWN CS, Ling FW. Significant advances in the management of PMS/PMDD (1989-1999). Reply to Dr. Townsend. OBG Management. 2000;January (Letter).
43. Parker NG, BROWN CS, Ling FW. Use of Selective Serotonergic Reuptake Inhibitors (SSRIs) in the Treatment of Premenstrual Syndrome. OBG Management: 2000 (March);67-71.



44. BROWN CS, Mitchel JT. Recruiting patients for female sexual arousal disorder studies. Journal of Sex and Marital Therapy, 2001;27(5):495-503.
45. BROWN CS. Depression and Anxiety Disorders. Primary and Preventive Care for the Obstetrician Gynecologist. Obstetrics and Gynecology Clinics of North America, 2001;28(2):7[1] - 7[28].
46. BROWN CS, Hill M. Psychotropic medications. Part 1: Use during pregnancy. The Female Patient, 2001;26:21-33.
47. Freeman E, Kroll R, Rapkin A, Pearlstein T, BROWN C, Parsey K, Zhang P, Patel H, Foegh M. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. Journal of Women's Health and Gender-Based Medicine, 2001;10:561-9.
48. BROWN CS. Premenstrual dysphoric disorder/premenstrual syndrome. The One Minute: Counselor. Journal of the American Pharmaceutical Association 2001 (Sep/Oct).
49. BROWN CS. Psychotropic medications. Part 2: Use during lactation. The Female Patient, 2002;27:27-38.
50. BROWN CS, Ling FW, Wan J. A new monophasic oral contraceptive containing drospirenone: Effect on premenstrual symptoms. Journal of Reproductive Medicine, 2002; 47:14-25.
51. BROWN CS, Ling FW, Pilla A, Wan J. Efficacy of static magnetic field therapy in chronic pelvic pain: A double-blind study. American Journal of Obstetrics and Gynecology, 2002; 187:15,81-87.
52. Borenstein JE, Dean BB, Endicott J, Wong J, BROWN C, Dickerson V, Yonkers KA. Health and economic impact of the premenstrual syndrome. Journal of Reproductive Medicine 2003;48:515-524.
53. Padma-Nathan H, BROWN C, Fendl J, Salem S, Yeager J, Harning R. Efficacy and safety of topical alprostadil cream for the treatment of Female Sexual Arousal Disorder (FSAD): A double-blind, multicenter, randomized, and placebo-controlled clinical trial. Journal of Sex & Marital Therapy 2003;29:329-344.
54. BROWN CS, Farmer R, and Soberman J, Eichner SF. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clinical Pharmacokinetics 2004;43(1):1-27.

55. McHorney CA, Rust J, Golombok S, Davis S, Bouchard C, BROWN C, Basson R, Sarti CD, Kuznicki J, Rodenberg C, Derogatis L. The profile of female sexual function (PFSF): A patient-based, international psychometric instrument for the assessment of hypoactive sexual desire in oophorectomized women. Menopause 2004;11(4):474-83.
56. Leiblum SR, BROWN CS, Wan, J, Rawlinson L. Persistent sexual arousal syndrome: A descriptive study. Journal of Sexual Medicine 2005; 2:331-337.
57. Buster JE, Kingsberg SA, Aguirre O, BROWN C, Breaux J, Buch A, Rodenberg CA, Wekselman K, Casson P. Testosterone patch for low sexual desire in surgically menopausal women: A randomized trial. Obstetrics and Gynecology 2005; 5(1):944-952.
58. BROWN CS, Bachmann. Treating Urogenital Atrophy. Women's Health. 2005 1(2):279-292.
59. Yonkers K, BROWN C, Pearlstein T, Foegh M, Sampson-Landers S, Rapkin A. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstetrics and Gynecology 2005;106:492-501.
60. Leiblum SR, BROWN CS, Wan, J. Persistent sexual arousal syndrome – A Response (Letter to the Editor). Journal of Sexual Medicine 2005; 2(5):745-746.
61. Likes WM, Stegbauer C, Hathaway D, BROWN C, Tillmanns T. Use of the Female Sexual Function Index in women with vulvar intraepithelial neoplasia. Journal of Sex and Marital Therapy 2006;32(3) 255-66.
62. Bachmann G, Rosen R, Pinn V, BROWN CS. Vulvodynia: Definitions, Diagnosis and Management: A State-of-the-Art Consensus. Journal of Reproductive Medicine 2006; 47(6):447-56.
63. BROWN CS, Glazer H, Vogt V, Menkes, D, Bachmann G. Subjective and objective outcomes of Botulinum Toxin Type A Treatment in Vestibulodynia: Pilot Data. Journal of Reproductive Medicine 2006; 49(8):635-41.
64. Leiblum S, Seehaus M, BROWN CS. Persistent genital arousal: Disordered or normative aspect of female sexual response? Journal of Sexual Medicine 2007; 4(3): 680-689.
65. Leiblum S, Seehuus M, Goldmeier D, BROWN CS. Psychological, medical and pharmacological correlates of persistent genital arousal disorder. Journal of Sexual Medicine 2007;4(5):1358-1366.
66. BROWN CS, Franks A, Ling FW, Wan J. An open label trial of citalopram in the treatment of women with chronic pelvic pain. Journal of Reproductive Medicine 2008; 53(3):191-195.

67. BROWN CS, Bachmann S, Wan J, Rosen R. Self-management, amitriptyline, and amitriptyline plus triamcinolone in the management of vulvodynia. Journal of Women's Health 2009, 18(2):163-9.
68. BROWN CS, Bachmann G, Ling FW. Differential diagnosis of seizure associated with topical lidocaine in a patient with vestibulodynia (Letter to the Editor). Journal of Lower Genital Tract Disease 2009; 13(1):51.
69. Moll J, BROWN CS. The Use of Monoamine Pharmacological Agents in the Treatment of Sexual Dysfunction: Evidence in the Literature. Journal of Sexual Medicine 2011; 8(4):956–970.
70. O'Brien PM, Backstrom T, BROWN C, Dennerstein L, Endicott J, Epperson CN Eriksson E, Freeman E, Halbreich U, Ismail KM, Panay N, Pearlstein T, Rapkin A, Reid R, Schmidt P, Steiner M, Studd J, Yonkers K. Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMO Montreal consensus. Arch Womens Ment Health 2011; 14(1):13-21.
71. Fabre LF, BROWN CS, Smith LC, DeRogatis LR, Gepirone-ER Treatment of Hypoactive Sexual Desire Disorder (HSDD) Associated with Depression in Women. Journal of Sexual Medicine 2011, 8(5):1411-9.
72. Rosen RC, Maserejian NN, Conner MK, Krychman M, BROWN CS, Goldstein I. Characteristics of premenopausal and postmenopausal women with acquired, generalized hypoactive sexual desire disorder: the Hypoactive Sexual Desire Disorder Registry for women. Menopause 2012, 19(4):396-405.
73. Brown CS, Bachmann GA, Foster DC Challenge in conducting a multicenter clinical trial: Experience in commencing a vulvodynia research protocol. J Women's Health 2013;22(3):291-2.
74. Balabathula P, Thoma LA, Nolly RJ, Horton FP, Stornes GD, Bhattacharjee H, BROWN CS, Foster DF, Bachmann G. Stability assessment study of capsaicin injection for intradermal administration. International J Pharmaceutics – submitted.
75. Brown CS, Foster DC, Rawlinson L, Bachmann GA. Rationale and design of a multicenter randomized clinical trial of extended release gabapentin in provoked vestibulodynia and biological correlates of response. Contemp Clin Trials - submitted
76. McDonald CS, Vuthipadadon S, Sakauye M, Rawlinson L, Brown C, Foster D, Bachmann G, Brooks IM. Validation tools for online CRF data capture in vulvodynia multisite clinical trial. In preparation.
77. BROWN CS, Ling FL, Foster DL, Bachmann GA. An open label trial of milnacipran in the treatment of provoked vestibulodynia. In preparation.

## OTHER PUBLICATIONS:

### Non Peer-Reviewed Journal Articles:

1. Rakel RE, BROWN CS. Latest pharmacologic Rx for anxiety disorders. Part 2. Medical Tribune, 1989;30:30.
2. Rakel RE, BROWN CS. Sorting out anxiety disorders. Part 1. Medical Tribune, 1989; 30:14,16.
3. BROWN CS, Ling FW, Farmer RG, Stone BF. Buspirone in the treatment of premenstrual syndrome. Drug Therapy, 1990; Aug(Suppl):112-21.
4. BROWN CS. PMS: A serotonergic syndrome. Topics in Psychiatry 1990;1(6):3,8.
5. BROWN CS, Cooke C. Attention deficit hyperactivity disorder. Current Therapeutics, 1995 (March).
6. BROWN CS. "A Pharmacist's guide to treating premenstrual disorders," The ACCP Report, 2002 (July).
7. BROWN CS. The Role of a Sex Therapist, In Female Sexual Health, Proctor & Gamble Regional Newsletter, 2005.
8. BROWN CS. Sexual Dysfunction. In Women's Health a Unique Challenge Coming into Awareness (ed H Haynie). Memphis Medical News, July 2005: pp 22-23
9. BROWN CS. Role of Sex Therapists. Midsouth Wellness Guide, July/August 2005; 34:14.
10. BROWN CS. Equal Opportunity. Memphis Magazine, February 2006; 55, 64.
11. Needle R, BROWN CS. Restoring Sexuality After Breast Cancer Coping Magazine, September/October 2007; 35.

### Research Reports:

1. BROWN CS. A comparison of the state dependent effects of electroconvulsive shock and physostigmine on a choice task. Master of Science in Psychology, Thesis, Central Washington University, Ellensburg, WA, 1973.
2. BROWN CS. Master of Science in Nursing, Thesis, University of Tennessee, Memphis, TN, 1996. Marital dynamics in women seeking treatment for premenstrual syndrome.

**Internal Publications:**

1. BROWN CS. Research suggests new hope and treatments for PMS. CAREspondence. University Physicians Foundation, Inc., 1989 (Nov/Dec).
2. BROWN CS. Carbohydrate craving and PMS. Health Care News. University of Tennessee of Publications, 1997 (May).
3. BROWN CS. Female sexual dysfunction. University of Tennessee Center for Women's Health Improvement (UTCWHI) Website, 2001 (October).
4. BROWN CS. Premenstrual Syndrome. University of Tennessee Center for Women's Health Improvement (UTCWHI) Website, 2001 (November).

**Abstracts Presented and Published:**

1. BROWN CS, Wright R, Christensen D. Association between type of medication instruction about neuroleptics and four outcome variables in chronic schizophrenic outpatients. Presented at the 19th Annual American Society of Hospital Pharmacists Midyear Meeting, Dallas, TX. December 1984. Published in American Journal of Hospital Pharmacy. 1984;41:2081.
2. Sitland PA, Wells BG, Rickman LA, BROWN CS. Anticholinergic drug abuse in community mental health. Presented at the Ninth Annual Meeting of the American College of Clinical Pharmacy, Philadelphia, PA. July 1988. Published in Pharmacotherapy. 1988;8:136.
3. Bryant SG, BROWN CS, Hokanson JA. Trazodone prescribing patterns for depressed inpatients. Presented at the Ninth Annual Meeting of the American College of Clinical Pharmacy, Philadelphia, PA. July 1988. Published in Pharmacotherapy. 1988;8:134.
4. BROWN CS, Wells BG, Self T, Jabbour JT. Influence of carbamazepine on plasma imipramine concentration in children with attention-deficit hyperactivity disorder. Presented at the Ninth Annual Meeting of the American College of Clinical Pharmacy, Philadelphia, PA. July 1988. Published in Pharmacotherapy. 1988;8:135.
5. Froemming SH, Cold JA, BROWN CS, Wells BG. Cost-effectiveness of support systems on medication knowledge, compliance and relapse rates in noncompliant schizophrenic outpatients. Presented at the 23rd Annual American Society of Hospital Pharmacists Midyear Meeting, Dallas, TX, December 1988. Published in American Journal of Hospital Pharmacy. 1988;45:2158.

6. Purdue L, Wells BG, Cold JA, Downs A, Rosenthal T, BROWN CS. Medication use and drug interactions in the elderly who live independently. Presented at the 24th Annual American Society of Hospital Pharmacists Midyear Meeting, Atlanta, GA, December 1989. Published in American Journal of Hospital Pharmacy. 1989;46:2262.
7. Cold JA, Wells BG, Marken PA, BROWN CS. A double-blind placebo-controlled study of the efficacy of nadolol in the treatment of antipsychotic-induced akathisia. Presented at the 24th Annual American Society for Pharmacists Midyear Meeting, Atlanta, GA, December 1989. Published in American Journal of Hospital Pharmacy. 1989;46:2266.
8. Wells BG, Cold JA, Marken PA, BROWN CS, Chu CC, Johnson R. Serum nadolol concentrations and antiakathisia response. Presented at the 91st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Francisco, CA. March 1990. Published in Pharmacotherapy. 1990;10:255-6.
9. BROWN CS, Cooke SC, Ling FW, Arheart KL. The role of neurotransmitter selectivity in the pharmacologic treatment of LLPDD. Presented at the Winter Practice and Research Forum of the American College of Clinical Pharmacy, Ft. Lauderdale, FL. February 1993. Pharmacotherapy, 1992;12:498.
10. BROWN CS, Ling FW, Anderson RN et al. Efficacy of depot leuprolide in premenstrual syndrome: Effect of symptom severity and type in a controlled trial. Published in Obstetrics & Gynecology 1994;84:779-786.
11. BROWN CS, Ling FW, Andersen RN, Farmer RG, Arheart KL. Effect of symptom severity and type on depot leuprolide efficacy in premenstrual syndrome. American College of Obstetricians and Gynecologists (ACOG), 42nd Annual Clinical Meeting, Orlando, Florida. May 1994. Published in Today in Medicine 1995;Jan/Feb:7.
12. BROWN CS, Ling FW, Anderson RN et al. Efficacy of depot leuprolide in premenstrual syndrome: Effect of symptom severity and type in a controlled trial. Published in Outcomes Research Digest 1995;1:6.
13. BROWN CS, Cooke C. Attention deficit hyperactivity disorder. Current Therapeutics, 1995 (March).
14. BROWN CS, Parker NG, Ling FW, Wan J. Sertraline in Contraceptive Users with PMDD. American College of Obstetricians and Gynecologists (ACOG), 48th Annual Clinical Meeting, San Francisco, California. May 2000. Published in Obstetrics & Gynecology 2000;95 (4, Suppl):29S.

15. BROWN CS, Parker NG, Ling FW, Wan J. Effect of Magnets on Chronic Pelvic Pain. American College of Obstetricians and Gynecologists (ACOG), 48th Annual Clinical Meeting, San Francisco, California. May 2000. Published in Obstetrics & Gynecology 2000;95 (4, Suppl):29S.
16. BROWN CS, Ling FW, Wan J. Effect of a new monophasic oral contraceptive on premenstrual symptoms. American College of Obstetricians and Gynecologists (ACOG), 50th Annual Clinical Meeting, Chicago, Illinois, April 2001. Published in Obstetrics & Gynecology, 2001; Apr Suppl.
17. BROWN CS, Ling FW, Pilla A, Wan J. Non-invasive static magnetic field therapy reduces chronic pelvic pain: A double-blind pilot clinical study. The Bioelectromagnetics Society 24<sup>th</sup> Annual Meeting, Quebec City, Quebec, Canada, June 2002. Published in Bioelectromagnetics, 2002; June Suppl.
18. BROWN CS, Ling FW, Johnson K, Glazer H, Vogt V, Wan J. Predictors of treatment outcome in women with vulvar vestibulitis syndrome. Abstract #74. American College of Obstetricians and Gynecologists (ACOG), 51st Annual Clinical Meeting, New Orleans, LA, 2003 (April). Published in Obstetrics & Gynecology, 2003; Apr Suppl.
19. Buster J, Kingsberg S, Aguirre O, BROWN C, Wekselman K, Casson P. Large phase III study confirms that transdermal testosterone patch 300 mcg/day significantly improves sexual function with minimal side effects in surgically menopausal women. National Endocrinology Society 86<sup>th</sup> Annual Meeting, New Orleans, LA 2004; Published in Journal of Clinical Endocrinology and Metabolism, 2004; June Suppl.
20. BROWN CS, Leiblum SR, Wan J, Rawlinson L. Comparison of sexual function in women with Persistent Sexual Arousal Syndrome, Female Sexual Arousal Disorder, and Healthy Controls using the Female Sexual Function Index. International Society for the Study of Women's Sexual Health 2005 Annual Meeting, Las Vegas, NV, 2005 (August); Published in Journal of Sexual Medicine, 2005;2(Suppl1).
21. BROWN CS, Glazer H, Vogt V, Menkes D, Bachmann G. Effect of Botulinum Toxin Type A on sexual function in vestibulodynia. Sexual Medicine Society of North America 2005 Fall Meeting, New York, NY, 2005 (November), Published in Journal of Sexual Medicine, 2006; 3(1):19.
22. BROWN CS, Bachmann S, Rosen R. Comparison of the efficacy of four interventions in the treatment of women with vulvodynia, International Society for the Study of Women's Sexual Health 2007 Annual Meeting, Orlando, FL, 2007 (February); Published in Journal of Sexual Medicine, 2007;4(Suppl 2)..

23. Levine SB, Brown C, Palace E, et al. Phase 2b Bremelanotide study of pre- and postmenopausal women with Female Sexual Arousal Disorder. American College of Obstetrician and Gynecologists (ACOG) 56<sup>th</sup> Annual Meeting, New Orleans, LA, 2008 (May). Published in Obstetrics and Gynecology, 2008 (Suppl, May).
24. Derogatis L, BROWN CS. Gepirone-ER treatment of symptoms of sexual dysfunction in women with major depressive disorder (MDD). Sexual Medicine Society of North America, Inc. (SMSNA) 15<sup>th</sup> Annual Meeting, San Diego, CA, 2009 (Nov). Published in Journal of Sexual Medicine, 2010;7(Suppl 1):43.
25. BROWN CS, Wan J, Bachmann G, Rosen R. The effect of amitriptyline compared to self-management on sexual function in women with vulvodynia (Poster #45). International Society for the Study of Women's Sexual Health (ISSWSH) Annual Meeting, St. Petersburg, FL, 2010 (Feb). Published in Journal of Sexual Medicine, 2010; 7(suppl 3):138.
26. BROWN CS. An open label trial of milnacipran in the treatment of women with provoked vestibulodynia – Research in progress. 36<sup>th</sup> Annual Meeting, Palm Beach, FL, 2011 (Mar). Published in Journal of Sex & Marital Therapy, 2011
27. Rosen R, Maserjian NN, Connor MK, Krychmann ML, BRWN CS, Goldstein I. The Hypoactive Sexual Desire Disorder Registry for women: Characteristics of premenopausal and postmenopausal women. International Society of Sexual Medicine/Sexual Medicine Society of North America (ISSM/SMSNA) Joint Annual Meeting, Chicago, IL, 2012 (Aug). Published in Menopause, 2012; 19(4), Poster 396.
28. Balabathula P, Wood G, Thoma L, BROWN C, Foster D, Bachmann G. Stability evaluation of capsaicin injection for intradermal administration. American Association of Pharmaceutical Sciences (AAPS) Annual Meeting , Chicago IL, 2012 (Nov).
29. McDonald CS, Vuthipadadon S, Sakauye M, Washington M, Rawlinson L, BROWN C, Foster D, Bachmann G, Brooks IM. Electronic Diary-Based Data Capture in a Pain Clinical Trial Data Management System. AMIA Summit on Clinical Research Informatics (CRI), San Francisco CA, 2013.
30. McDonald CS, Vuthipadadon S, Kuscu E, Sakauye M, Brooks IM, Washington M, BROWN CS, Foster D, Bachmann G. A Web Based Recruiting System for Clinical Pain Trials. American Academy of Pain Medicine (AAPM) 29<sup>th</sup> Annual Meeting, Fort Lauderdale, Florida (Apr) 2013.



**Abstracts Presented but not Published:**

1. Solovitz BL, Fisher S, Bryant SG, Kluge RM, BROWN CS. Patient accuracy in detecting adverse drug reactions. Presented at the Annual Meeting of the Texas Medical Association, Forum of Original Research, Dallas, TX. 1986 (May).
2. Bryant SG, Rose RM, Fisher S, Felthous AF, Barratt E, BROWN CS. Effects of phenytoin and lithium in violent patients. Presented at the Annual Meeting of the Texas Medical Association, Forum of Original Research, Dallas, TX. 1986 (May).
3. Rose RM, Bryant SG, Amadeo M, Barratt E, Felthous AF, Fisher S, BROWN CS. Effects of lithium and phenytoin on violent behavior. Presented at the Annual Forensic Psychiatry and Law Conference, Galveston, TX. 1986 (November).
4. DeLapp T, Boggs P, BROWN CS. A comparison of drug therapy knowledge, as shown for three prototype drugs among nurses of varying educational and experiential backgrounds. Presented at the Annual Meeting of the Alaska Nurses' Association, Anchorage, AK. 1986 (December).
5. BROWN CS, Bryant SG, Kent TA. The biology of episodic aggression: Blood platelet and red blood cell studies. Presented at the First Annual Meeting of the Southwest Leadership Conference for Pharmacy Residents, Fellows and Preceptors, Dallas, TX. 1987 (April).
6. Kent TA, BROWN CS, Bryant SG, Felthous A, Barratt E, Rose RM. Serotonin blood platelet uptake and episodic aggression. Presented at the Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico. 1987 (December).
7. Bryant SG, Felthous AR, Wingerter CB, Rose RM, Barratt E, Fisher S, BROWN CS. Diagnostic issues in recruitment of subjects for outpatient trials of antiaggressive drugs. Presented at the Annual Meeting of the American Academy of Forensic Sciences, Philadelphia, PA. 1988 (February).
8. Froemming SH, Cold JA, BROWN CS, Wells BG. Cost-effectiveness of support systems on medication knowledge, compliance, and relapse rates in noncompliant schizophrenic outpatients. Presented at the Second Annual Meeting of the Southwest Leadership Conference for Pharmacy Residents, Fellows and Preceptors, Dallas, TX. 1988 (March).
9. Blumer DP, BROWN CS. Postictal depressive episodes. Presented at the Annual Meeting of the American Epilepsy Society, Boston, MA. 1989 (December).

10. Hutcherson HW, BROWN CS, Lupfer M. Cognitive mediating factors of stress and coping in premenstrual syndrome. Presented at the Graduate Research Forum, Memphis State University, 1990 (February).
11. Lancaster EM, BROWN CS, Helms RA, Sibai BM, Ling FW. Effect of diet on mood in buspirone-treated as compared to placebo-treated PMS patients. Presented at the 18th Annual Meeting of the American Society for Psychosomatic Obstetrics and Gynecology, New York, NY. 1990 (May).
12. BROWN CS, Chesney CM, Ling FW, Wells BG, Kitabchi AE. Buspirone response in PMS and platelet 5-HT uptake. Presented at the 143rd Annual Meeting of the American Psychiatric Association, New York, NY. 1990 (May).
13. BROWN CS, Chesney CM, Ling FW. Buspirone in the treatment of premenstrual syndrome. Presented at the 30th Annual Meeting of the New Clinical Drug Evaluation Unit Program (NCDEU), NIMH sponsored, Key Biscayne, FL. 1990 (May).
14. Ling FW, BROWN CS. Clinical phenomenology of PMS: Implications for the physician in a nonpsychiatric specialty area. Presented at the Fourth Annual NIMH International Research Conference on the Classification and Treatment of Mental Disorders in General Medical Settings, Bethesda, MD. 1990 (June).
15. Wells BG, BROWN CS, Chesney CM, Ling FW, Barratt ES. Anger and impulsivity in premenstrual syndrome: Response to buspirone and relationship to serotonin uptake. Presented at the 92nd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, San Antonio, TX. 1991 (March).
16. BROWN CS, Ling FW. The clinical presentation of premenstrual syndrome: A mental health perspective. Presented at the 39th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, New Orleans, LA. 1991 (May).
17. BROWN CS, Ling FW. Prolactin response to TRH during buspirone treatment in premenstrual syndrome. Presented at the 39th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists, New Orleans, LA. 1996 (May).
18. BROWN CS, Ling FW, Chesney CM, Farmer R. History and biology predict LLPDD subtypes. Presented at the 144th Annual Meeting of the American Psychiatric Association, New Orleans, LA. 1991 (May).

19. BROWN CS, Ling FW, Farmer R. Efficacy of depot leuprolide in PMS as a function of serotonin and symptom type. Presented at the 31st Annual Meeting of the New Clinical Drug Evaluation Unit Program (NCDEU), NIMH sponsored, 1991 (May).
20. BROWN CS, Chesney CM, Ling FW, Wells BG. Mood changes and platelet 5-HT uptake in PMS. Presented at the 93rd Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Orlando, FL. 1992 (March).
21. BROWN CS, Blumer D, Wyler R. Mood changes and subarachnoid 5-HIAA levels in TLE. Presented at the 145th Annual Meeting of the American Psychiatric Association: Washington, D.C. 1992 (May).
22. BROWN CS, Ling FW, Chesney CM. Efficacy and pharmacologic mechanism of buspirone in premenstrual syndrome. Presented at the 21st Annual Meeting of the American College of Clinical Pharmacology, Washington D.C. 1992 (September).
23. BROWN CS, Ling FW. Methodological problems in PMS treatment studies: An evaluation of buspirone efficacy. Presented at Sixth Annual NIMH International Research Conference on Primary Care Mental Health Research: Concepts, Methods, and Obstacles. Washington, D.C. 1992 (October).
24. BROWN CS, Wright CW, Blumer D, Cooke SC, Arheart KL. A Comparison of imipramine and placebo in the control of dysthymic and anxious affects associated with temporal lobe epilepsy. Presented at the Winter Practice and Research Forum of the American College of Pharmacy, Ft. Lauderdale, FL. 1993 (February).
25. BROWN CS, Stentz FB, Ling FW, Chesney CM. Hypothalamic-pituitary axis, buspirone, and LLPDD. American Society of Clinical Pharmacology and Therapeutics (ASCPT), 94th Annual Meeting, Honolulu, Hawaii. 1993 (March).
26. Hutcherson HW, BROWN CS. Cognitive mediating factors of stress in premenstrual syndrome. Midwestern Psychological Association, 65th Annual Meeting, Chicago, IL. 1993 (April).
27. Halbreich U, Freeman E, BROWN CS, Pearlstein T. Efficacy of sertraline for treatment of premenstrual disorder. American Psychiatric Association (APA), 148th Annual Meeting, Miami, Florida. 1995 (May).
28. Yonkers KA, Halbreich U, Freeman EW, BROWN CS, Pearlstein TB. Efficacy of sertraline for treatment of premenstrual dysphoric disorder, 35th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU), NIMH sponsored, Orlando, FL. 1995 (May).

29. Halbreich U, Freeman, E, BROWN CS, Pearlstein TB. Efficacy of sertraline for treatment of premenstrual dysphoric disorder. Second International Conference on New Directions in Affective Disorders, New Research Poster Sessions, Jerusalem, Israel. 1995 (September).
30. Yonkers KA, Halbreich U, Freeman E, BROWN CS, Pearlstein T. Efficacy of sertraline for treatment of premenstrual dysphoric disorder. Second International Conference on New Directions in Affective Disorders. Jerusalem, Israel, 1995 (September).
31. BROWN CS, Scandrett-Hibdon S. Marital dynamics in women seeking treatment for premenstrual syndrome. Theory Construction and Research Methodology Workshop (TCRM). Kansas City, MO, 1996 (November).
32. Pearlstein T, Halbreich U, BROWN CS. Psychosocial functioning in women with premenstrual dysphoric disorder and after treatment with sertraline or placebo. Oral slide presentation, New Research Abstract., #650 American Psychiatric Association Annual Meeting, Toronto, Canada, 1998 (June).
33. BROWN CS, Mitchel JT. Recruiting patients for female sexual arousal disorder studies. The 1999 New Perspectives in the Management of Female Sexual Dysfunction International, Multi-disciplinary Meeting. Boston, MA, 1999 (October).
34. Rosen R, BROWN CS, Jieman J, et al. Validation of a female sexual dysfunction. The 1999 New Perspectives in the Management of Female Sexual Dysfunction International, Multi-disciplinary Meeting. Boston, MA, 1999 (October).
35. BROWN CS, Ling FW, Wan J. An open label trial of citalopam in the treatment of women with chronic pelvic pain. Oral slide presentation. The International Pelvic Pain Society's (IPPS) 9<sup>th</sup> Scientific Meeting on Chronic Pelvic Pain. San Diego, CA, 2002 (June).
36. Shabsigh R, BROWN C, Fendl J, et al. A Phase 2 clinical study examining the efficacy and safety of a novel topical alprostadil cream for the treatment of Female Sexual Arousal Disorder (FSAD). Oral slide presentation. The International Society for the Study of Women's Sexual Health (ISSWSH). Vancouver, British Columbia, Canada, 2002 (October).
37. BROWN C, Vogt V, Menkes D, Ling F, Glazer H, Curnow J. An open label trial of botulinum toxin type A in treating women with vulvar vestibulitis syndrome. Poster presentation. The International Society for the Study of Women's Sexual Health (ISSWSH). Amsterdam, Netherlands, 2003 (October).

38. Leiblum SR, BROWN CS. A descriptive study of women with persistent sexual arousal syndrome. Poster presentation. The International Society for the Study of Women's Sexual Health (ISSWSH). Atlanta, GA, 2004 (October).
39. BROWN CS, Vogt V, Menkes D, Bachmann G, Glazer H. Subjective and objective outcomes of Botulinum Toxin Type A in Vulvar Vestibulitis Syndrome. Vulvodynia and Sexual Pain Disorders in Women Conference, Atlanta, GA, 2004 (October).
40. Likes W, Stegbauer C, Hathaway D, BROWN C, Tillmanns T. Validation of the female sexual function index in women with VIN after excision. Beta Theta Chapter of Sigma Theta Tau, Memphis, TN, 2005 (February).
41. Likes WM, Stegbauer C, Tillmans T, Hathaway D, BROWN C. Validation of the Female Sexual Function Index in women with vulvar intraepithelial neoplasia after excision. Annual Meeting of the American Society for Reproductive Medicine and the Canadian Fertility and Andrology Society, Montreal, Quebec, Canada, 2005 (October).
42. Fortenberry T, BROWN CS, Wan J, Ling FW. A Comparison of type and severity of premenstrual symptoms occurring in African American and Caucasian women with premenstrual dysphoric disorder. National Medical Association Scientific Assembly, Honolulu, Hawaii, 2007 (August).
43. Pinn V, Bachmann G, Utian WH, Rosen R, Brown C. Vulvodynia: Furthering clinical and research needs through a consensus model. American Academy of Pain Management 18<sup>th</sup> Annual Meeting, Las Vegas, NV, 2007 (September).
44. Derogatis L, Koltun W, BROWN C et al. Validation of the Inventory of Sexual Events and Desire (ISED) Diary. North American Menopausal Society (NAMS) 16<sup>th</sup> Annual Meeting, Dallas, TX, 2007 (October).

**Abstracts Published but not Presented:**

1. Wells BG, Marken PA, Rickman LA, BROWN CS, Hamann G, Grimmig J. Characterizing anticholinergic abuse in community mental health. Psychopharmacology Bulletin 1990;26:223.
2. BROWN CS, Lancaster EM, Ling FW, Arheart KL, Boehm KA, Helms RA. Effect of diet type and drug group on tryptophan/LNAA ratios and mood in PMS. Journal of Cellular Biochemistry 1992 (suppl 16B).
3. BROWN CS. Treatment of ADHD; A critical review. Pharmacy Digest, In: HH Van Osdol (ed), Clinical Digest Series, 1992.

4. Woodrum ST, BROWN CS. Cited in: Human Sexuality. Management of SSRI-Induced Sexual Dysfunction (Review). 1999 (January).
5. Markowitz JS, BROWN CS, Moore TR. Atypical antipsychotics Part 1: Pharmacology, pharmacokinetics, and efficacy. The Database of Abstracts of Reviews of Effectiveness (DARE). NHS Center for Reviews and Dissemination. University of York, York, UK, 5/9/00.

#### **Audiovisual Productions:**

1. BROWN CS, Rodack J. Health Call: Premenstrual Syndrome (Audiotape). Memphis, TN: University of Tennessee Medical Group; 1997.
2. BROWN CS, Rodack J. Health Call: Menopause and Depression, (Audiotape). Memphis, TN: University of Tennessee Medical Group; 1998.
3. Horn H, Ke R, BROWN CS, Carbone L, Nabors D, Mullins B, Langsdon P, Wallace R, Hickerson W. Today's Healthy Woman. (Videotape). Memphis, TN: University of Tennessee Medical Group and WREG News Channel 3; 1999.
4. BROWN CS, Rodack J. Health Call: Female Sexual Disorders, (Audiotape). Memphis, TN: University of Tennessee Medical Group, 1999.
5. BROWN CS, Weesner B. A Matter of Health: Female Sexual Disorders, (Audiotape). WMC AM 790, Memphis, TN, 1999.
4. BROWN CS, Ling F, Naruponjirakul N, Foster D, Bachmann G. Diagnosis of Vulvodynia in the Infertile Woman with Dyspareunia. International Federation of Societies and the American Society for Reproductive Medicine (IFFS/ASRM) Annual Meeting, Boston, MA, Oct 2013 (submitted).

#### **Educational Media:**

1. BROWN CS, RJ Evans, JR Dell, M Lee. Is it Really another UTI? Interstitial Cystitis and the Pharmacist's Role in Identifying the Patient at Risk. Supported by University of Tennessee College of Pharmacy. Advanced Studies in Pharmacy, 2005 (March).
2. BROWN CS. Advances in the Treatment of Premenstrual Dysphoric Disorder (PMDD): A multidisciplinary continuing-education Program. Supported by an unrestricted educational grant from Lilly. Power-Pak Communications, 2001 (June).
3. Yuzpe AA, BROWN CS, Hietkemper M. Beyond Contraception – Enhancing the Quality of Life: A continuing medical education program. Supported by an unrestricted educational grant from Berlex Laboratories, Inc. MedPro Communications, Inc., 2002 (March).

4. BROWN CS, "The use of oral contraceptives in the treatment of PMS/PMDD," in Yonkers KA, Dickerson VM, Reissman D, BROWN C. Demystifying PMS: The Chemical/Hormonal Spectrum: A continuing medical education program. A Virtual Lecture Series. Supported by an unrestricted educational grant from Berlex Laboratories, Inc. Parexel Medical Marketing Services, 2002 (June).
5. BROWN CS, Evans RJ, Dell JR, Lee M. Is it really another UTI? Interstitial cystitis and the pharmacist's role in identifying the patient at risk. Advanced Studies in Pharmacy. Galen Publishing, Somerville, NJ; 2005.